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Abstract: Communication between cells is crucial to preserve body homeostasis and health. Tightly
controlled intercellular dialog is particularly relevant in the gut, where cells of the intestinal mucosa
are constantly exposed to millions of microbes that have great impact on intestinal homeostasis by
controlling barrier and immune functions. Recent knowledge involves extracellular vesicles (EVs) as
mediators of such communication by transferring messenger bioactive molecules including proteins,
lipids, and miRNAs between cells and tissues. The specific functions of EVs principally depend on
the internal cargo, which upon delivery to target cells trigger signal events that modulate cellular
functions. The vesicular cargo is greatly influenced by genetic, pathological, and environmental
factors. This finding provides the basis for investigating potential clinical applications of EVs as
therapeutic targets or diagnostic biomarkers. Here, we review current knowledge on the biogenesis
and cargo composition of EVs in general terms. We then focus the attention to EVs released by
cells of the intestinal mucosa and their impact on intestinal homeostasis in health and disease.
We specifically highlight their role on epithelial barrier integrity, wound healing of epithelial cells,
immunity, and microbiota shaping. Microbiota-derived EVs are not reviewed here.
Keywords: extracellular vesicles; exosomes; gut communication; gut immunity; intestinal homeostasis;
miRNAs
1. Introduction
Communication between cells is crucial to preserve body homeostasis and health.
This is particularly relevant in the intestinal tract, where host cells are exposed to millions
of bacteria and food antigens [1]. Besides cell-to-cell contacts and soluble released factors
that can act locally or distantly on other cells types and tissues, extracellular vesicles (EVs)
can mediate intercellular crosstalk. EVs are a heterogeneous population of lipid bilayer
membrane-enclosed vesicles that transport and deliver proteins, lipids, and nucleic acids to
recipient cells. There are multiple classes of EVs released from almost all cell types and they
can also be found in various biological fluids. Initially, the release of EVs was considered
a mechanism to discard unwanted materials from cells. However, intensive research has
revealed that release of EVs has a pivotal role in cell-to-cell communication in human
physiology and pathology. Here, we discuss current knowledge on the production and
cargo composition of EVs and focus the attention on EVs released by cells of the intestinal
mucosa, highlighting their impact on intestinal homeostasis in health and disease.
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2. Biogenesis and Composition of EVs
2.1. Classification of EVs
The term EVs comprise a varied, heterogeneous group of particles released from cells
that largely originate from endosomes and/or plasma membrane with complex cargoes [2].
The classification of EVs has been inconsistent and confusing. In fact, isolation methods
for EV subtypes are still under development and consensus on best practices has not yet
been reached. However, according to the International Society for Extracellular Vesicles
(ISEV), minimal requirements must be met to assert the presence of EVs in sample isolates,
and several experiments need to be conducted to characterize the existence of EVs [3].
Thereby, on the basis of current studies on the mechanism of formation, mode of release
from cells, and size, we can describe three categories: (i) exosomes, (ii) microvesicles (MVs),
and (iii) apoptotic bodies. Although vesicle size is the main factor used in EV categorization,
some reports have demonstrated that EVs within one EV class may be heterogenic in terms
of cargo and functionality.
Exosomes are small EVs defined as 30–200 nm lipid bilayer particles secreted by all
cell types [4]. Recent studies have shown two novel subpopulations of exosomes, including
large exosome vesicles (Exo-L) with 90–120 nm diameter, small exosomes vesicles (Exo-S)
with 60–80 nm diameter, and an abundant population of non-membranous nanoparticles
called exomeres with sizes around 35 nm [5]. Exosomes can be found in almost all living
cells, including dendritic cells, lymphocytes, mast cells, intestinal epithelial cells, and
endothelial cells. Moreover, exosomes can be detected and isolated from various body
fluids such as urine, plasma, cerebrospinal fluid, human milk, and exudates [6]. Exosomes
originate first as intraluminal vesicles (ILVs) within a multivesicular body (MVB), which
are released into the extracellular matrix after MVB fusion with the plasma membrane.
This process operates through the endosomal pathway [7]. Due to their origin, exosomes
differ from other EVs that are released from the cell as the result of a direct budding process
of the plasma membrane.
MVs, also called microparticles or ectosomes, are defined as 200–1000 nm vesicles
released by vesiculation from eukaryotic cells [8]. They are formed by outward blebbing
of the plasma membrane and subsequently released via actomyosin-driven fission of
plasma membrane blebs. Initially, MVs were described as “platelet dust”, due to their
identification as subcellular material originating from platelets in normal plasma and
serum [9]. MVs derived from human cancer cells are called “oncosomes” (1–10 µm) and
have a role in cell–cell communication. Their ability to participate in the horizontal transfer
of signaling proteins and mediators contributes to invasive activity in cancer [10]. Although
oncosomes are classified within MVs; this group is studied separately due to their larger
size, characteristic biomolecules, and isolation methods.
Apoptotic bodies include much larger vesicles of 1–5 µm and they are formed during
membrane blebbing and cellular disassembly from fragmentation when the cytoskeleton
breaks at the beginning of apoptosis [11]. Their impact upon other cells is not well studied.
Nonetheless, it has been suggested that apoptotic bodies participate in immune regulation,
including processes such as autoimmunity, cancer, and infection [12]. This group will be
excluded from this review.
2.2. Biogenesis of EVs
It is known that EVs are formed by multiple mechanisms that are summarized in Figure 1.
Exosomes are generated within the endosomal system and microvesicles are formed by
outward budding vesicles at the plasma membrane. Although the generation of EVs
(exosomes or microvesicles) occurs at distinct sites within the cell, common intracellular
mechanisms are involved in the biogenesis of both entities.
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Figure 1. Schematic overview of extracellular vesicle (EV) biogenesis and cargo. At least three different subclasses of EVs
are generated by eukaryotic cells: exosomes (30–200 nm), microvesicles (200–1000 nm), and apoptotic bodies (1–5 µm).
The left panel schematically shows the biogenesis pathway for each EV type. Microvesicles and apoptotic bodies sprout
directly from the plasma membrane, whereas exosomes are generated within multivesicular body (MVB) subpopulations
that upon maturation fuse with the plasma membrane. The biogenesis pathway influences the cargo of EVs. In particular,
the composition of exosomes is presented in the right panel. Exosomes are rich in the adhesion molecules tetraspanins
(CD9, CD81, CD63), antigen-presenting molecules (MHCI/II), membrane transport proteins (annexins, flotillin), enzymes
(elongation factors, metabolic enzymes), and other cytosolic proteins (ribosomal proteins). In addition, lipids (sphingomyelin
and phosphatidylserine) and nucleic acids (DNA, RNA, non-coding RNAs (ncRNAs), and micro-RNAs (miRNAs)) also are
bioactive components.
Exosomes are derived from endosomal compartments. Within the endosomal system,
endosomes are divided into compartments including early endosomes, late endosomes,
and recycling endosomes. To release exosomes, plasma membrane and cytosol-associated
molecules (lipids, proteins, and nucleic acids) are endocytosed and transferred into early
exosomes, which fuse with endocytic vesicles sorting their cargo for degradation, recycling,
or secretion. The remaining early exosomes differentiate into late exosomes that give
rise to ILVs formed by inward budding of the endosomal membrane. In turn, ILVs are
enclosed within MVBs. These can either fuse with lysosomes if their content is destined for
degradation, or merge with the cellular membrane, releasing the ILVs as exosomes into the
extracellular space [13].
The exosome biogenesis pathway can be regulated by various mechanisms. One well-
known mechanism involves the endosomal sorting complex required for transport (ESCRT)
that is needed for MVB formation as it classifies ubiquitinated intracellular cargos that
are destinated for lysosomal degradation into MVBs [14]. The ESCRT machinery consists
of four multiprotein complexes (ESCRT 0, I, II, and III) and accessory proteins (TSG101,
ALIX, Vps4, and VTA1). Although ESCRT units are released into the cytosol for recycling,
some accessory proteins such as TSG101, HRS, and ALIX remain in exosomes as markers.
Alternatively, recent evidence has shown that ESCRT-independent mechanisms exist for
exosome formation and release that are based on neutral sphingomyelinase (nSMase)-
dependent ceramide formation. This lipid could facilitate membrane invagination of ILVs
through its cone-shaped structure [15,16]. Moreover, proteins from the tetraspanin family
such as CD9, CD63, CD81, and CD82 are regulators of ESCRT-independent endosomal
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sorting. For instance, it has been reported that CD63 allows for sorting of a melanosomal
protein in ILVs in human melanoma cells [17].
The mechanism involved in the secretion of EVs formed by direct budding from
the plasma membrane, such as MVs, is less well characterized and has only started to
emerge. Evidence has revealed that recruitment of the ESCRT-I subunits TSG101 and Vps4
to the plasma membrane through binding to a tetrapeptide protein within the Arrestin 1
domain-containing protein 1 (ARRDC1) results in the release of MVs containing TSG101,
ARRDC1, and other cellular proteins [18]. Several factors such as redistribution of phos-
pholipids including reposition of phosphatidylserine to the outer leaflet, contraction of
actin/myosin machinery, and extracellular concentration of Ca+2 can impact MV formation
and alter membrane fluidity and deformability [19]. In addition, enzymes that transfer
lipids from one leaflet of the plasma membrane to the other such as flippases, floppases,
and scramblases play an important role in MV development [20].
EVs are released to the extracellular space due to the presence of Rab proteins, which
are essential regulators of intracellular vesicle transport between compartments. Rabs
can be involved in vesicle budding, trafficking through interaction with the cytoskeleton,
or docking to the membrane of an acceptor compartment [21]. Secreted EVs establish inter-
actions with recipient cells and transmit the information. The interaction can be through
ligand/receptor molecules on their respective surfaces mediated by classical adhesion
molecules including integrin and intracellular adhesion molecules. Additionally, EVs
can deliver their content by endocytic processes such as clathrin- and caveolin-mediated
endocytosis, lipid raft endocytosis, phagocytosis, and micropinocytosis, probably guided
by vesicle membrane composition and surface molecule profile [22].
2.3. Components of EVs
The biochemical composition of EVs has been studied in several populations and
likely depends on the mode of biogenesis, cell type, and physiological conditions. Like-
wise, the isolation methods that are used can influence the composition of EVs. Thus,
characterization of all their components remains unclear. Recent technology advances and
new methodologies such as proteomics, lipidomics, and transcriptomics have allowed the
identification of different types of cargos in EVs (Figure 1). The derived information has
been integrated in several databases such as Exocarta [23], Vesiclepedia [24], and EVpe-
dia [25], which serve as repositories and tools that help to decipher vesicle loading and
functions. Overall, all EVs are loaded with proteins, lipids, and nucleic acids, and their
cargo can be specific to the vesicle and cell type. This section will describe the content of
EVs in general terms.
Proteins: The protein cargo of EVs in various cell types has been extensively re-
viewed [26,27]. Diverse proteomics analyses of exosomes have identified proteins associ-
ated with the biogenesis mode, including proteins linked to the endosomal pathway [28].
In fact, components of ESCRT have been found in exosomes, including ALIX, TSG101,
and HRS [29]. In addition, proteins involved in the trafficking and release of EVs such
as RAB27A, RAB11B, and ARF6 are commonly identified [30]. As mentioned above, EVs
are rich in tetraspanin proteins including CD63, CD81, and CD9, which are being used
as exosome markers. These proteins can target specific cells, such as endothelial cells,
to promote angiogenesis [31]. In addition, several metabolic enzymes such as ATPase,
glyceraldehyde-3-phosphate dehydrogenase, enolase-1, and pyruvate kinase type M2 have
been detected in EVs by proteomic analysis [32]. Likewise, heat shock proteins including
HSP70 and HSP90 and major histocompatibility complex (MHC I and II) are found in EVs
derived from most cell types and are involved in antigen binding and presentation [31].
Lipids: The content of lipids in EVs are not fully characterized, but in general it is
known that lipid composition shares common features with the origin cells. Outstanding re-
views about this topic are available in the literature [33,34]. It has been suggested that some
lipids can be specifically associated with different types of EVs, depending on whether
they originate from MVB or from plasma membrane [35]. In general, EVs are rich in phos-
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phatidylcholine, phosphatidylserine, phosphatidylethanolamine, phosphatidylinositols,
phosphatidic acid, cholesterol, ceramides, sphingomyelin, glycosphingolipids, and other
less abundant lipids [36]. Exosomes are rich in phosphatidylserine facing the extracellular
milieu, an attribute that likely facilitates their internalization by recipient cells [37]. A single
universal marker for MVs is less well defined. However, ARF-6 and CD40 are frequently
found in MVs derived from tumor cells [38]. Since EVs are membrane-limited vesicles,
their lipid bilayer has a protective function that preserves internal cargo from proteolytic
or RNAase degradation.
Nucleic acids: Recent research has demonstrated a varied composition of genetic
material in EVs. Diverse studies have found genomic DNA, complementary DNA (cDNA),
and transposable elements in extracellular vesicles [39]. Currently, research is focused
on RNA content. Extensive scientific evidence shows that EVs carry functional RNAs
that play a pivotal role in cell-to-cell communication and regulation of cellular processes.
In this sense, EVs contain mRNAs, non-coding RNAs (ncRNAs) including micro-RNAs
(miRNAs), small nuclear RNAs (snRNAs), and transfer RNAs (tRNAs) [40]. In particular,
miRNAs exported through EVs have a relevant role since they can post-transcriptionally
regulate gene expression in distant cells [41–43]. In this context, a database called EV
miRNAs has been created with data from multiple studies analyzing miRNA expression
profiles in various types of EVs from distinct cell types [44]. Since exosomal miRNAs play
a pivotal role in several diseases, have great stability, and reach a high concentration in
circulation, they have great potential as disease biomarkers for diagnosis or prognosis, and
as therapeutic targets [8,45].
3. Intercellular Communication by EVs in Intestinal Homeostasis
Intestinal homeostasis depends on complex, dynamic interactions between the micro-
biota, the epithelium, and the host immune system. Given the complexity of the intestinal
ecosystem, regulatory mechanisms involving immune receptors, signaling pathways, reg-
ulatory proteins, and miRNAs are required to ensure symbiosis and avoid exacerbated
inflammatory responses that could lead to pathological states. In this scenario, intercel-
lular communication is crucial to orchestrate balanced responses to preserve intestinal
homeostasis.
There is mounting evidence that intra- and interkingdom crosstalk is mediated by
EVs released by gut microbiota or by host intestinal cells. This review is focused on host-
derived EVs. It is well known that cargos in EVs confer specific properties and functions.
For instance, the presence in EVs of metalloproteinases (MMPs), chemokines, cytokines,
growth factors, adhesion molecules, and miRNAs plays a crucial role in processes involving
the immune system. Differences in the amount of released EVs and their composition
have been observed in health and disease states. High levels of EVs with different content
were found in samples from patients with inflammatory bowel disease (IBD), which
suggests their contribution to intestinal inflammatory processes [46]. The role of EVs
as messengers in cell-to-cell communication inside the body is not limited to the gut
environment. As mentioned above, it is now well accepted that circulating EVs can reflect
diverse healthy and pathologic states of cells and tissues. Therefore, they are being explored
as diagnostic biomarkers or therapy tools in several disorders.
In the following sections, we summarize the functions and contribution of host-
derived EVs to intestinal homeostasis and immune cell function, according to the available
literature. We focus on epithelial barrier integrity, repair and wound healing of epithelial
cells, immunity, and microbiota shaping.
3.1. EVs Modulate Epithelial Barrier Integrity
The mucosa surface in the gastrointestinal tract comprises a single layer of intestinal
epithelial cells (IECs) that is optimized to efficiently absorb nutrients, water, and electrolytes
from food. Moreover, this epithelial layer creates an interface that protects from invading
pathogens and prevents the ingress of luminal harmful substances. Disruption of this
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barrier results in increased intestinal permeability, which facilitates the translocation of
antigens and bacteria into the bloodstream. Thus, in some diseases of inflammatory
origin such as IBD, loss of intestinal barrier function causes tissue injury by an excessive
inflammatory response in the gut wall.
EVs play a crucial role in regulating epithelial barrier integrity. Disruption of the
intestinal epithelial barrier results in epithelial injury and subjacent inflammation caused
by migration of macrophages and polymorphonuclear cells (PMN) across IECs [47]. Exper-
imental evidence indicates that leukocyte migration can affect tight junction (TJ) proteins
in IBD [48]. In fact, loss of several key components of the apical junctional complex (AJC)
including occludin, claudins, and zonula occludens (ZO) proteins occurs in locations of
inflamed tissue with abundant transmigrating neutrophils [49]. It has been shown that
PMN-derived soluble mediators such as EVs contribute to these processes, activating the
immune response and specific pathways of inflammation depending on their content [50].
Cargo proteins in EVs influence epithelial barrier integrity. Under inflammatory
conditions, PMN-derived EVs contain high amounts of MMP-9, a matrix metalloproteinase
that mediates negative effects on IEC integrity. MMP-9 disrupts the epithelial barrier
by cleaving proteins involved in intercellular adhesions such as desmoglein-2 (DSG-2),
a protein that is crucial for barrier integrity through several mechanisms. DGS-2 is linked
to the actin cytoskeleton through interactions with adapter proteins and provides structural
support for epithelial monolayers. In addition to its adhesion function, DSG-2 regulates
intestinal barrier function via p38 MAPK signaling and is required for proper localization
of ZO-1 [51,52]. In IECs, DGS-2 has a barrier function that prevents PMNs migration.
In the inflamed epithelium, the MMP-9 enzyme contained in EVs released by PMNs
degrades DGS-2, thus enabling PMN trafficking across epithelial layers [51]. Conversely,
macrophages recruited to intestinal inflamed sites may contribute to tissue homeostasis,
as they release EVs with high content in galectin-3 (Gal-3). In macrophages, Gal-3 export
through exosomes is regulated by reactive oxygen species and nicotinamide adenine
dinucleotide phosphate (NADPH) oxidase-dependent superoxide production activity [53].
This lectin interacts with and stabilizes DSG-2 at the intercellular adhesion sites, which
contributes to IEC barrier integrity [54]. In addition, EVs mediate cross-regulation between
activated PMNs and macrophages. It has been shown that PMN-derived EVs are taken up
by macrophages, leading to rapid Ca+2 flux and release of TGF-β1. By these mechanisms,
PMN-derived EVs regulate the immunomodulatory properties of macrophages [55].
Proinflammatory cytokines cause intestinal barrier disruption. A study conducted in
luminal aspirates of IBD patients showed that granulocyte-derived EVs release cytokines
such as IL-6, IL-8, and TNF-α. In vitro assays revealed that these EVs are taken up by
colonic epithelial cells and activate the expression of IL-8, which in turn promotes migration
of a high number of macrophages to the IBD epithelium [56]. In addition, it is known that
TNF-α increases epithelial permeability via mislocalization of TJ proteins including ZO-1,
claudins, and occludin through the activation of the ERK1/2 signaling pathway [57].
The cellular prion protein (PrPC) is released in exosomes from activated platelets
that participate directly in cell-to-cell transmission [58]. PrPC is located in cell-to-cell
junctions and interacts with desmosome proteins in the intestinal epithelium. Indeed, mice
deficient in PrP have greater paracellular permeability than wild-type mice. Alterations in
barrier function were also confirmed in in vitro cultures of PrPc knockdown colonic Caco-2
cell monolayers. PrPC deficiency results in decreased levels of E-cadherin, desmoplakin,
plakoglobin, claudin-4, occludin, ZO-1, and tricellulin at intercellular contacts in colonic
cell monolayers [59]. Interestingly, PrPC localization is altered in colonic epithelia from
patients with IBD.
miRNAs in EVs influence epithelial barrier integrity. EVs can also transport miRNAs,
which are small non-coding RNAs that modify post-transcriptionally the expression of a
huge number of proteins in target cells. These regulatory RNAs bind to complementary
sequences at the 3′-untraslated region (UTR) of target mRNAs and interfere with protein
synthesis by triggering mRNA degradation or blocking its translation. Several miRNAs
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have been involved in the regulation of AJC and epithelial barrier dysfunction in intestinal
inflammation diseases, such as Crohn’s disease (CD) and ulcerative colitis (UC) [60,61].
In blood, the presence of these miRNAs correlates with their expression changes in the in-
flamed gut mucosa. Circulating miRNAs are mainly secreted through exosomes, although
some reports show that they can also be distributed in association with the RNA-binding
protein argonaute-2 or high density lipoproteins (HDL) [62,63]. Here, we consider miRNAs
known to be secreted through EVs.
One miRNA deregulated in IBD is miR-21. Increased levels of this miRNA have
been found in samples of IBD patients [64,65]. During colonic inflammation, activation
of the neuropeptide Substance P signaling pathway triggers miR-21 sorting through ex-
osomes released by colonic epithelial cells [66]. In vitro studies in human colonic cell
lines have indicated that miR-21 has a destructive effect on the intestinal barrier, regulat-
ing TJs’ permeability through the PTEN/PI3K/Akt signaling pathway. In epithelial cell
monolayers, overexpression of this miRNA downregulates occludin and E-cadherin but
increases production of prostaglandin E2, IL-6, and IL-8 [67]. Studies performed in an
in vivo intestinal barrier dysfunction model induced by ischemia reperfusion confirmed
the correlation between upregulation of miR-21 and loss of barrier integrity. Consistently,
levels of the TJ proteins occludin and claudin-1 were reduced in the intestinal tissue of
treated animals. In this model of barrier disruption, production of IL-6, TNF-α, intercellular
adhesion molecule-1 (ICAM-1), and myeloperoxidase (MPO) was also increased [68]. In ex-
perimental colitis, miR-21 was shown to control intestinal barrier function by regulating
the expression of Ras-related small GTP-binding protein B (RhoB) and cell division control
protein 42 (CDC42). Thereby, attenuated expression of miR-21 in gut could prevent barrier
disruption and the progression of subjacent inflammatory process [69].
Another miRNA upregulated in IBD is miR-223. Serum levels of miR-223 are higher
in CD and UC patients than in healthy controls [70,71]. The IL-23 pathway is important
for the onset of IBD since it causes downregulation of claudin-8, an important protein that
conforms the structure of intestinal TJs. In a 2,4,6-trinitrobenzene sulfonic acid (TNBS)-
induced colitis model in mice, miR-223 was identified as a mediator of the IL-23 pathway
that suppresses the activity of claudin-8. Treatment of colitic mice with antagomir-223
restored the levels of claudin-8 and improved the clinical symptoms of sick mice [72]. Mast
cells play a critical role in development of IBD. A recent study showed that exosomes from
human mast cells are loaded with miR-223, and that delivery of this miRNA into IECs
downregulates the expression of the TJ-related proteins ZO-1, occludin, and claudin-8,
which in turn elicit the subsequent increase in intestinal permeability that contributes to
inflammation and disease development [73].
High levels of miR-29a, miR-122, and miR-874 have also been found in blood, small
bowel, and colon tissues of IBD patients and other pathological conditions associated
with increased intestinal permeability. Although their secretion through EVs has not
specifically been investigated in IBD, all these miRNAs have been found deregulated
in blood circulating exosomes from colorectal cancer patients [74–76]. These miRNAs
modulate intestinal epithelial barrier through several mechanisms by targeting TJ proteins
and key regulatory factors. Concerning miR-29a, one of the mechanisms is downregulation
of glutamine synthetase [77]. In gut samples of IBD patients, overexpression of miRNA-29a
also reduces the expression of the TJ protein claudin-1 and the transcriptional silencer
protein nuclear factor-κB-repressing factor (NκRF). This leads, respectively, to epithelial
barrier disruption and highly deregulated transcriptional activity of proinflammatory
mediators [78]. Another cellular process regulated by miR-29a is apoptosis. Intestinal
epithelial apoptosis is a common histopathological feature of inflammation-related diseases.
In UC patients and UC experimental models, miRNA-29 triggers apoptosis of IECs by
downregulating anti-apoptotic protein Mcl-1 of the BCL-2 family [79]. Remarkably, miR-
29a is also exported through DC-derived EVs [80]. In fact, miR-29 participates in immunity
as a key player in the interaction of DCs with T cells. In this case, the targets are molecules
involved in antigen presentation and release of cytokines [81].
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MiR-122a was also detected in clinical specimens of IBD. This miRNA modulates sig-
naling pathways that control intestinal permeability by targeting epidermal growth factor
receptor (EGFR). Downregulation of EGFR leads to increased levels of zonulin, a modulator
of intestinal epithelial TJs that increases intestinal permeability [82]. In addition, miR-122
binds to occludin mRNA, promoting its degradation and the subsequent depletion of
occludin, which in turn destabilizes the epithelial barrier [83].
Overexpression of miR-874 in ischemic injury has damaging effects on barrier integrity
leading to subsequent increased intestinal permeability. This miRNA downregulates
aquaporin 3, a protein expressed in gut epithelia with an important role in the integration
of TJ complex structure. In this pathological model, high levels of miR-874 also correlated
with reduced levels of mucin-2 and the TJ proteins occludin and claudin-1 [84].
3.2. EVs Are Involved in Tissue Repair, Mucosal Healing, and Cell Proliferation
In mucosal wounds, EVs from IECs and immune cells can locally modify the ex-
pression of growth and transcription factors to control cell migration, proliferation, and
differentiation, promoting epithelial healing and tissue repair [85]. Upon injury, a succes-
sion of events occurs in epithelial mucosa to bring about wound closure. These involve
recruitment of immune cells and release of proteins and mediator molecules. Annexin
A1 (ANXA1) is a potent endogenous pro-resolving mediator that facilitates resolution of
inflammation and orchestrates wound repair through the formyl-peptide receptor-like
pathway. It has been shown that ANXA1-deficient animals exhibit increased suscepti-
bility to dextran sulphate sodium (DSS)-induced colitis with greater clinical morbidity
and histopathologic mucosal injury [86]. IEC-derived exosomes contain ANXA1 that fa-
cilitates tissue repair by binding to formyl peptide receptors (FPRs) in responsive cells.
Activation of this pathway leads to generation of ROS by the epithelial NADPH oxidase
NOX1, which in turn controls the activation of focal adhesion mediators [87]. Release of
ANXA1-containing EVs increases during wound closure and in IBD patients with acute
inflammation and injury. In an experimental in vivo model, the application of exogenous
ANXA1 mimetic peptide (Ac2-26) encapsulated in polymeric nanoparticles enhanced heal-
ing of murine colonic wounds and improved recovery from induced colitis [88]. Likewise,
PMN-derived extracellular vesicles containing ANXA1 mediate anti-inflammatory effects
by preventing PMN adhesion to endothelial cells and inhibiting recruitment of PMN to
inflamed tissue. Overall, these activities limit progression of the inflammatory process and
help its resolution [89].
EVs isolated from the mucosal–luminal interface of IBD patients also contain high
levels of the enzyme MPO [90]. Whereas ANXA1 participates in colonic repair, MPO
generates reactive oxidants. This activity is beneficial for killing invading pathogens,
but in the case of unsuitable or excessive stimulation, it contributes to acute and chronic
inflammation [91]. In this context, PMN infiltration of the intestinal mucosa frequently
results in severe epithelial injury. Microvesicles released by these immune cells contain
highly active MPO, which upon delivery to IECs inhibits wound closure by impairing
IEC migration and proliferation [92]. In addition, MPO associated with PMN-derived EVs
enhance the inflammatory response through activation of IL-6, IL-8, and MCP-1 secretion
by IECs, which facilitates leukocyte recruitment and triggers the upregulation of adhesion
molecules. Besides proinflammatory EVs that help other immune cells to reach damaged,
inflamed sites, neutrophils secrete EVs with anti-inflammatory functions to limit the exces-
sive immune responses of neighboring cells such as macrophages, monocytes, and natural
killer (NK) cells [93]. The impact of neutrophil microvesicles loaded with MPO on other
cell types has also been reported. Exposure of human umbilical vein endothelial cells to
these EVs results in disturbances in membrane integrity and morphological changes [94].
Moreover, M2 macrophages are involved in the resolution of inflammation and intestinal
repair. These immune cells promote proliferation of colonic epithelial cells and wound
healing in an exosome-dependent manner, which involves miR-590-3p. This miRNA acti-
vates transcription of YAP-regulated gens by targeting the serine/threonine protein kinase
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LATS1. In addition, miR-590-3p blocks activation of pro-inflammatory cytokines such as
TNF-α, IL-1β, and IL-6 [95].
Other immune cells release EVs with wound healing activity on endothelial cells. In a
diabetic rat model, macrophage-derived EVs were shown to accelerate re-epithelialization
of diabetic lesions. The mechanism is related with their anti-inflammatory effects, which
diminish the production of proinflammatory cytokines (IL-6 and TNF-α) and enzymes
(MMP-9). TGF-β is one of the mediators secreted by macrophages as part of the inflam-
matory response. Regardless of its role in immune function, TGF-β also participates in
tissue repair. In the presence of this cytokine, fibroblasts in damaged inflamed lesions
undergo phenotypic differentiation to myofibroblasts, which contributes to wound heal-
ing [96]. In the same way, exosome-containing TGF-β released by injured epithelial cells
activate fibroblasts to initiate tissue regeneration responses. Indeed, these exosomes trigger
cell proliferation together with production of type I collagen and expression of F-actin
by fibroblasts. The resulting fibrosis and increased matrix deposition at the injury site
contribute to wound healing [97].
Fibroblasts promote epithelial cell motility through the cell surface tetraspanin CD81.
In breast cancer, fibroblast-derived EVs contain CD81 and trigger signaling events to confer
cancer cells’ invasive behavior [98]. The Wnt signaling pathway has a relevant role in the
regulation of intestinal epithelial cell proliferation [99]. In fact, WNT/β-catenin is activated
to maintain homeostasis and achieve wound closure in intestinal epithelium [100]. Some
components of this pathway can be secreted into exosomes from gut epithelial and im-
mune cells. For instance, Wnt5b is secreted within exosomes derived from Caco-2 cells.
The Wnt5b-associated exosomes were shown to activate cell migration and proliferation of
other cancer cells in a paracrine manner [101]. Similarly, macrophages generate exosomes
containing Wnt5b that are crucial for the regeneration response in the gut. Following radia-
tion injury, these exosomes activate enterocyte survival through the WNT pathway [102].
Another essential protein controlling IEC migration and proliferation is glycoprotein
A33 (GPA33). This is a specific cell surface marker with properties in cell-to-cell communi-
cation, including cell adhesion, trafficking, and immune response. GPA33 is expressed in
normal stomach, small intestine, colon, and rectal epithelial cells, and in almost all colon
cancer. For this reason, it has been proposed as a potential biomarker for diagnosis and
prognosis of colorectal cancer [103]. There is evidence that GPA33 modulates intestinal
barrier integrity. GPA33 knockout mice show impaired epithelial barrier function, with
quick onset and delayed resolution of DSS-induced colitis. In addition, in this experimental
model of colitis, GAP33 deficiency correlates with an increased number of colitis-associated
tumors following treatment with the colon-specific mutagen azoxymethane [104]. Studies
using the 2,4,6-trinitrobenzene sulfonic acid/ethanol-induced colitis model confirmed the
role of GPA33. In this experimental model, mice deficient in GPA33 also showed impaired
ability to resolve tissue damage due to delayed epithelial cell proliferation and weakened
adaptative immunity. Consistently, GPA33-deficient mice showed higher mortality than
wild-type mice following colitis induction [105].
3.3. EVs Orchestrate Regulation of Intestinal Immunity
3.3.1. IEC-derived EVs
IECs release vesicles from the apical and basolateral sides. Mounting evidence indi-
cates that IEC-derived EVs serve as crucial messengers for intercellular communication in
the gut. These vesicles transport diverse molecules that participate in crosstalk with the
immune system to maintain intestinal homeostasis (Figure 2). This activity is at least in
part conferred by mediators that are expressed on the surface of EVs, such as molecules
involved in the antigen presentation function. Although IECs are not specialized antigen-
presenting cells (APC), an analysis of samples from small intestinal biopsies showed that
IECs constitutively express MHC I and MHC II, HLA-DM, CD63, CD68, A33, and other
molecules typically found in exosomes derived from professional APCs. These molecules
confer antigen sampling and processing capacities on IECs. Their intracellular distribution
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and trafficking points to their secretion through exosomes released from the basolateral
compartment of the normal gut epithelium [106]. Secretion of immune molecules involved
in antigen presentation by IEC-derived EVs was also evidenced in human and murine IEC
lines. In the human HT-29 and T-84 cell lines, the expression of MHC I and MHC II and the
release of EVs containing these immune mediators was shown to be upregulated by inflam-
matory signals [107]. In the murine epithelial cell line MODE K, released exosomes also
display MHC I/II peptides and other immune markers such as CD9, CD81, CD82, and A33
antigen and were able to activate immunogenic or tolerogenic immune responses depend-
ing on the exosome-expressed epitopes [108]. Thus, IEC-derived exosomes may influence
antigen presentation in the intestinal mucosa independently of direct interaction with the
effector immune cells. In this context, exosomes derived from the intestinal epithelial
cell line T-84 have been shown to establish communication with DCs, which in turn elicit
T-cell activation. Whereas direct presentation of IEC-derived exosomes to lymphocytes
is ineffective in driving appropriate responses, exosome interaction with DCs produces
stronger peptide presentation to T cells [109]. Taken together, these studies indicate that
EVs released from the basolateral side of enterocytes are independent antigen-carrying
entities that connect detection of luminal antigens with the local immune system [110].
Figure 2. Modulation of immune responses by EVs originated from intestinal epithelial and immune cells. Schematic
view of the intestinal mucosa showing the epithelium and the underlying immune system. These host cells receive
information from microbiota mainly through secreted factors and lumen antigens that can diffuse through the mucus layer
and initiate appropriate immune responses. In this scenario, EVs are key for the host to communicate with neighboring cells.
Intestinal epithelial cells (IECs) release EVs from the basolateral side (colored in brown) that participate in the crosstalk
with lymphocytes and dendritic cells, being able to activate naïve T cells towards immunogenic (Th) or tolerogenic (Treg)
responses depending on the exosome-expressed epitopes and cargo. DCs are the main antigen-presenting cells in the gut
lamina propria. These immune cells can integrate information either directly from the intestinal lumen or transmitted
through EVs secreted by other cell types under healthy and pathological conditions (intestinal infections, inflammation,
or cancer). Once activated, DCs secrete EVs (colored in purple) containing MHC and costimulatory molecules that mediate
antigen presentation and immunomodulatory effects towards CD4+ or CD8+ T cells, eliciting suitable T cell responses.
IEC-derived EVs can also drive tolerogenic responses in the gut. This activity has been
associated with integrin αvβ6, whose expression is upregulated in IECs in response to lu-
minal antigens. Remarkably, exosomes released by IECs act as carriers of food and luminal
antigens. Studies performed in both mice and intestinal epithelial cell lines challenged to
ovalbumin as a food antigen revealed that IEC-derived exosomes loaded with αvβ6 and
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OVA could prime DCs to produce a high amount of active TGF-β and promote generation
of regulatory T (Treg) cells. In contrast, DCs challenged directly with OVA in the absence
of IEC-derived EVs express high levels of the inactive form of TGF-β, known as latent
TGF-β. In fact, integrin αvβ6 delivered by IEC-derived EVs plays an important role in
the conversion of latent TGF-β into the active form in DCs. Moreover, these exosomes
inhibit in vivo Th2 immune responses towards food antigens. These findings proved that
IEC-derived exosomes carrying αvβ6 and food antigens are part of intestinal immune
mechanisms involved in the development of tolerance to foreign antigens [111].
Under physiological conditions, IEC-derived EVs are also loaded with TGF-β1. In a
mice model of IBD, administration of these vesicles ameliorates inflammation by inducing
immunosuppressive DCs and Treg cells, whereas inhibition of EV production in vivo
aggravates IBD. These IEC-derived EVs mainly localize with the epithelial cell adhesion
molecule (EpCAM) within the intestinal tract. This association is relevant, since the
protective effects of TGF-β1-rich EVs are dampened in EpCAM knockout mice. In addition,
the severity of IBD was higher in EpCAM-deficient animals than in wild-type mice [112].
Conversely, when EVs are released by injured epithelial cells they promote immune
dysfunction. It has been shown that when trauma and hemorrhagic shock occurs, rat gut
epithelial cell-derived exosomes alter the maturation and function of DCs by increasing
cell apoptosis and decreasing the expression of CD80 and CD86 surface markers and their
capacity to drive T-cell responses through antigen presentation [113].
3.3.2. EVs Derived from Immune Cells
DCs are recognized as the main antigen-presenting cells in the gut lamina propria and
can integrate signals from the intestinal lumen and shape appropriate immune responses.
In addition to direct sampling of luminal microbes, DCs receive information from EVs
released by other cell types and/or tissues under healthy and pathological conditions that
include intestinal infections, inflammation, or cancer. IECs are key players in this indirect
pathway of communication, since once activated by an external stimulus they transmit
the information to the underlying immune cells by releasing EVs and soluble mediators
(Figure 2). Then, activated DCs elicit suitable T-cell responses through antigen presentation
and secretion of specific cytokines. In this context, activated DCs secrete EVs containing
MHC class I and class II complexes and costimulatory molecules that contribute to antigen
presentation and immunomodulatory effects towards CD4+ or CD8+ T cells.
Initial studies on DC-derived EVs showed that injection of DC-derived exosomes
to mice induced antigen-specific naïve CD4+ T-cell activation, whereas in in vitro mod-
els of cell culture only exosomes derived from mature DCs expressing CD80 and CD86
costimulatory markers could trigger appropriate naïve CD4+ activation. In fact, these
exosomes allow the exchange of functional MHC complexes between DCs, which provides
a mechanism to magnify adaptive immune responses [114]. Similarly, exosomes derived
from DCs challenged with lipopolysaccharide (LPS), but not exosomes from immature
DCs, were shown to be loaded with MHC class II, B7.2, and intercellular adhesion molecule
1 (ICAM-1). Functional studies also revealed that the presence of these immune molecules
in the exosomes is required for their capacity to prime naive T cells [115]. Like other cell
types, human DCs produce different kinds of EVs. The proteomic analysis of the heteroge-
neous EVs population showed that some molecular markers, such as MHC-I/II, flotillin,
and heat shock 70-kDa proteins, are similarly present in all EVs, whereas other proteins are
mainly associated with a particular vesicle subtype. For instance, exosomes are enriched in
tetraspanins CD9, CD63, and CD81 compared to other extracellular vesicles. In fact, these
molecules have been proposed as exosome surface markers for immune-based separation
methods [31,116]. Functional studies to characterize the effect of EVs isolated from primary
DC cultures revealed that both large EVs and small EVs secreted from mature DCs could
induce CD4+ T cell activation in vitro. In contrast, vesicles secreted by immature DCs
differed in T-helper-driven responses. Large EVs promoted secretion of Th2 cytokines
whereas small EVs prompted Th1 cytokine secretion. Nevertheless, these differences were
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no longer observed following DC maturation, and all EVs were able to induce INF-γ and
the subsequent Th1 response [117].
Besides DCs, other immune cells participate in the maintenance of intestinal home-
ostasis, and their regulation is crucial for controlling inflammation and IBD pathogenesis.
For instance, EVs from granulocytic myeloid-derived suppressors cells (G-MDSC) at-
tenuated DSS-induced colitis in mice. Treated animals showed reduced infiltration of
inflammatory cells in the damaged mucosa. Moreover, treatment with G-MDSC-derived
exosomes results in increased production of Treg cells in mesenteric lymph nodes together
with decreased amount of Th1 cells, and lower serum levels of the proinflammatory cy-
tokines TNF-α and INF-γ. These effects were associated with arginase-1 contained in
derived exosomes [118]. Wong et al. (2016) stimulated macrophages RAW264.7 with exo-
somes isolated from serum of DSS-treated colitic mice to analyze how circulating exosomes
may contribute to the pathogenesis of IBD. Comparison with stimulations performed with
serum exosomes from control mice revealed that exosomes from colitic mice activated
proinflammatory signaling cascades and triggered upregulation of TNF-α production [119].
A proteomic analysis identified 56 differentially expressed proteins in exosomes from colitic
mice, most of them related with processes involved in macrophage activation, such as the
complement system and the coagulation pathway [119].
The role of PMN cells in tissue repair and leukocyte trafficking during inflammation
is well-established. They release potent antimicrobial agents that cause degranulation.
Simultaneously, PMNs release cell surface-derived microvesicles with different functions
in cell-to-cell communication. PMN-derived EVs modulate the maturation and function
of macrophages and DCs during inflammatory processes. Stimulation of immature DCs
with PMN-derived EVs results in cell morphology changes, reduction of DC phagocytic
activity, and increased TGF-β1 release. In addition, PMN-derived EVs partially inhibit
the maturation of DCs exposed to LPS. Under these conditions, activated DCs showed
decreased secretion of inflammatory cytokines such as IL-8 and IL-6, as well as reduced
capacity to induce T-cell proliferation [120]. A lipidomic study performed in phagocytes
revealed that the lipid mediator profile of the released EVs differs between cell types and
maturation stages. The study showed specific regulation of PMN-derived EV production
by lipid mediators during the stages of the inflammatory process, which determine rapid
resolution of inflammation [121]. Macrophage-derived EVs carry leukotrienes, which are
potent inflammatory mediators participating in granulocyte recruitment. The expression
of leukotriene biosynthesis enzymes in macrophages and subsequent leukotriene exosome
release are upregulated by TGF-β1 [122].
Besides immunomodulatory effects, EVs released by infiltrating PMN mediate patho-
logical effects in the intestinal mucosa. This is particularly relevant in IBD. These EVs can
cause genotoxicity with clear implications for cancer development. PMN-induced geno-
toxicity has been attributed to oxidative stress generated by the release of reactive oxygen
species. Recent evidence has indicated that PMN-derived EVs can also contribute to these
effects by a different mechanism. PMN-derived EVs carry the proinflammatory miRNAs
miR-23a and miR-155, which, upon intracellular delivery to IECs, promote double-strand
breaks in DNA by targeting key regulators of the homologous recombination repair system.
The increase in such lesions in damaged epithelium leads to impaired mucosa healing and
genomic instability that in turn accelerate the progression of colorectal cancer [123].
3.3.3. EVs Derived from Mesenchymal Stem Cells
Recent studies show the therapeutic potential of mesenchymal stem cells (MSCs)
against autoimmune and inflammatory diseases. The capacity of MSCs to modulate pheno-
type and function of immune cells largely depends on secreted EVs [124]. Several reports
indicated that administration of EVs derived from MSCs isolated from different sources
that include bone marrow, umbilical cord, or olfactory lamina propria ameliorate experi-
mental colitis in mice [125–131]. In all these models, animals treated with MCS-derived
EVs showed preserved intestinal barrier integrity, reduced infiltration of inflammatory cells
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in the damaged mucosa, reduced secretion of pro-inflammatory cytokines, and expansion
of Treg cells. Several vesicular factors and mechanisms have been shown to mediate these
effects. Concerning EVs released by bone marrow derived MSCs, the mechanism involved
downregulation of NF-κB p65 and the oxidative stress enzymes iNOS and COX-2 in injured
colon. Additionally, these EVs also repressed apoptosis by inhibiting proteolytic cleavage
of diverse caspases in colitis [127]. Cao et al. (2019) evidenced that amelioration of colitis
by bone marrow MSC-derived EVs is associated with their ability to induce polarization of
colon macrophages into the immunosuppressive M2 phenotype. The increase in colonic IL-
10 and TGF-β levels allows for repair and regeneration of intestinal epithelial barrier [129].
Among the multiple exosome-containing proteins that could mediate the anticolitic effects,
metallothionein-2 was shown to be required to suppress inflammatory responses [126].
Studies performed with human umbilical cord MSCs revealed new mechanisms responsi-
ble for the anti-inflammatory effects of the derived exosomes in experimental models of
IBD. These mechanisms involve modulation of post-translational modifications of proteins,
including ubiquitination and neddylation, thus controlling conformation and stability
of target proteins [125,130]. Neddylation refers to the covalent binding of a ubiquitin-
like protein to the target proteins by the sequential action of three enzymes in a process
that resembles ubiquitination. However, this modification does not target the protein for
degradation but promotes conformational changes that impact on protein interactions and
activity. Wang et al. (2020) showed that miR-326, which is highly expressed in exosomes
derived from umbilical cord MSCs, plays a relevant role in inhibiting neddylation and
NF-κB signaling in murine experimental IBD [125].
Intestinal inflammation is closely associated with epithelial barrier disruption. In-
terestingly, exosomes derived from MSCs contain miR-34a/c-5p and miR-29b-3p, which
improve intestinal barrier function by targeting the transcriptional repressor Snail (Table 1).
Both miRNAs and several claudins are downregulated in damaged human intestinal tis-
sues. Following exosome uptake, miR-34a/c-5p and miR-29b-3p activate expression of
claudin-3, claudin-2, and ZO-1 in IECs [132].
3.3.4. Immune Regulation by EV-Associated miRNAs
As mentioned above, besides lipidic and peptide mediators, EVs also carry regulatory
RNAs. By this mechanism, miRNAs can be transferred between cells and mediate target
gene repression. In this context, miRNAs modulate gene expression of effector molecules
involved in innate and adaptative immune responses. In fact, dysregulation of known
master regulators of inflammation and immunity, such as miR-155 and miR-146, is a general
trait in IBD [133]. Both miRNAs are released from DCs within exosomes and are transferred
between immune cells in vivo [134].
In IBD patients with colorectal cancer, overexpression of miR-155 has been detected
in neoplastic and non-neoplastic mucosa sections, which suggests a connection between
dysregulation of this miRNA and the risk of IBD patients to develop colorectal cancer.
Upregulation of miR-155, and of miR-21, promotes microsatellite instability by targeting
the main proteins involved in the mismatch repair pathway [135]. Acute experimental
models of colitis using miR-155-deficient animals confirmed the role of miR-155 in assist-
ing proinflammatory responses in IBD. Relative to wild-type mice, deficiency in miR-155
weakened the severity of colitis by altering inflammatory cellular responses. Remarkably,
knockout mice had decreased production of local and systemic inflammatory cytokines,
and reduced numbers of CD4+ T cells involved in Th1 and Th17 responses [136]. Other
studies were conducted to identify the targets regulated by miR-155 in IBD models. In IBD,
intestinal myofibroblasts greatly contribute to mucosal damage. Pathak et al. (2015) in-
vestigated the role of miR-155 in inflamed myofibroblasts and its modulation in UC. The
study showed that miR-155 is upregulated in myofibroblasts from biopsies of UC patients
compared to healthy control samples. In intestinal myofibroblasts isolated from control
subjects, expression of miR-155 is increased by treatment with proinflammatory mediators
such as TNF-α and LPS, whereas TGF-β1 does not modify miRNA expression [137]. In this
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model, the suppressor of cytokine signaling 1 (SOCS-1) was identified as the main direct
miR-155 target responsible for the inflammatory effects. SOCS1 is a proven feedback in-
hibitor of inflammation, and its downregulation by miR-155 leads to increased production
of inflammatory cytokines such as IL-6 and IL-8. This study revealed the mechanism
involving miR-155 in UC progression. Inflammatory mediators induce miR-155 expres-
sion in intestinal myofibroblasts of UC patients. In turn, this miRNA downregulates the
expression of SOCS1, which supports the inflammatory phenotype [137]. SOCS-1 is not
the only miR-155 target associated with the IBD phenotype. In vitro studies performed in
macrophage cell lines such as Raw264.7 and primary bone marrow-derived macrophages
have shown that miR-155 effects on proliferation and release of proinflammatory cytokines
are associated with downregulation of the SH2-containing inositol 5′-polyphosphatase
(SHIP-1), an important negative regulator of the PI3K-Akt signaling pathway. The role of
SHIP-1 as mediator of miR-155 inflammatory effects was confirmed in experimental models
of colitis. Colitic mice administered with antagomir-155 showed increased SHIP-1 expres-
sion and reduced intestinal inflammation [138]. Taken together, available experimental
evidence points to miR-155 as a potential therapy target in IBD.
Another crucial actor in immune regulation is miRNA-146, which post-transcriptionally
regulates the expression of toll-like receptors and downstream molecules of their signal-
ing pathways in different subtypes of intestinal epithelial and immune cells. Whereas
miR-155 contributes to colitis and mucosal damage, miR-146a suppresses inflammation
in experimental models of inflammation. A study performed in an endotoxin-induced
inflammation model in mice provided evidence that miRNAs exported through exosomes
undergo functional transfer between cells and regulate the inflammatory response. In this
in vivo model of inflammation, the administration of exosomes carrying miR-146a reduced
TNF-α and IL-6 serum levels compared to mice that received miR-146a-deficient exosomes.
In addition, the amount of miR-146a found in tissues such as bone marrow, liver, and
spleen, was higher in mice that received exosomes containing miR-146a. Consequently, the
expression of miR-146a targets such as IRAK-1 and TRAF-6 was repressed in the tissues of
the treated animals [134]. The miR-146 family includes miR-146b, which originated from
a different chromosome, and as its counterpart mediates anti-inflammatory effects in the
intestine. In the DSS-induced colitis model, administration of miR-146b intraperitoneally
enhances epithelial barrier function, relieves intestinal inflammation, and improves the
survival rate of treated mice. These effects depend on the NF-κB activation that follows
miR-146b-mediated downregulation of Siah2, a protein involved in the ubiquitination of
proteins involved in signal transduction from several TNF receptors [139]. Another feature
attributed to miR-146a is its protective role against ischemia/reperfusion injury in small
intestine. Plasma and intestinal tissue samples from patients with mesenteric ischemia
showed lower miR-146a expression levels than controls. Downregulation of miR-146a
correlated with upregulation of its targets TLR4, TRAF6, and nuclear NF-κB p65, and with
high levels of activated caspase-3. Conversely, upregulation of miR-146a in rat IECs caused
an increase in survival and decreased cell apoptosis, together with downregulation of its
targets. These findings prove the role of miR-146a in improving intestinal epithelial cell
survival in ischemia reperfusion injury [140].
As stated above, upregulation of miR-223 in IBD is related with its secretion through
mast cell-derived exosomes. Besides its role in controlling barrier integrity, miR-223 acti-
vates NF-κβ signaling and production of proinflammatory cytokines, which exacerbates the
progress of IBD. This miRNA suppresses IκBα levels (NF-κβ inhibitor) through downregu-
lation of its target FOXO3a [141]. Although these findings indicate a positive correlation
between upregulation of miR-223 and IBD development, its exact role in intestinal inflam-
mation is controversial since deficiency of miR-223 has been related to high susceptibility to
develop induced colitis in mice. The miR-223-deficient mice exhibited reduced levels of con-
ventional DCs and macrophages that express the chemokine CX3CXR. These macrophages
are present throughout the intestinal tract and display high phagocytic activity, which pro-
tects the host against infections [142]. Moreover, miR-223 has been shown to limit intestinal
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inflammation by targeting NLRP3 inflammasome expression in monocytes to inhibit IL-1β
production during murine colitis. Reduced IL-1β levels result in amelioration of injury and
improvement of clinical and histological signs of colitis [143]. These controversial findings
point to a role of miR-223 in the control of intestinal homeostasis by modulating innate
immune responses during inflammation.
Other less described miRNAs such as miR-16 and miR-10a could be important in
the physiological control of inflammation. These miRNAs have been found as exoso-
mal circulating miRNAs in serum of healthy mice. These exosomes were shown to be
originated from different tissues including the intestine [144,145]. In humans, miR-16 is
highly expressed in UC [146]. The effects of this miRNA may be attributed, at least par-
tially, to downregulation of its target adenosine A2a receptor (A2aAR), which is essential
for adenosine-mediated inhibition of the NF-κB signaling pathway during inflammation.
Transfection of HT-29 cells with miR-16 mimics confirmed translocation of NF-κβ p65 into
the nucleus and the subsequent release of inflammatory cytokines. In contrast, treatment
with an miR-16 inhibitor counteracted miR-16-derived effects [147]. Some reports point to
miR-10a as another of the miRNA regulating immune pathways in the intestinal environ-
ment that could play a role in the pathogenesis and progression of IBD. This miRNA has
been found in lower amounts in samples from patients with IBD. Consequently, miR-10
targets such as NOD2 and IL-12/IL-23p40 were upregulated in IBD patients compared
to controls. Treatment with anti-TNF-α antibodies markedly increases the expression
of miR-10 and downregulates the expression of NOD2 and IL-12/IL-23p40 in inflamed
mucosa. Besides these effects, miR-10a inhibits DC activation and suppresses Th1 and
Th17 cell immune responses [148]. Similar findings were observed in mice with colitis.
These animals expressed higher levels of IL-12/IL-23p40 and lower levels of intestinal
miR-10a than control mice. Interestingly, expression of miR-10a is downregulated by gut
microbiota through the MyD88-dependent pathway, providing in this way a mechanism
that contributes to the maintenance of intestinal homeostasis [149].
Treg cells have been shown to exert beneficial effects on IBD through a mechanism
that depends on miR-195a-3p secreted through exosomes. In fact, this miRNA is highly
expressed in Treg-derived exosomes. Liao et al. (2020) showed that Treg exosomes alleviate
the severity of IBD in mice challenged with dextran sodium sulphate by transferring miR-
195a-3p into IECs. This miRNA inhibits apoptosis by targeting caspase-12, allowing cell
proliferation and repair of the intestinal epithelial barrier [150].
Overall, these findings indicate that host-derived EVs can influence intestinal home-
ostasis and orchestrate immune responses in different T cell phenotypes. Since the
molecules delivered through EVs differ depending on external stimuli or pathological
status, the derived response can be positive or negative, protecting or injuring the host.
Scientific evidence in this field is increasing and greatly contributes to the understanding
of exosome mechanisms, which may lead to exosome-based approaches for IBD therapy.
3.4. EVs Released by Cells of the Intestinal Mucosa Shape and Modulate Gut Bacteria
3.4.1. Control of Enteric Pathogens
Recent evidence has suggested that IEC-derived EVs could confer protection against
enteropathogenic infections, helping barrier integrity restoration and pathogen clearance.
In the context of intestinal infection, the parasite Cryptosporidium parvum activates produc-
tion and luminal secretion of exosomes by infected IECs. The mechanism involves TLR-4
signaling, which promotes the SNAP23-associated vesicular exocytotic process. In addi-
tion, exosomes are loaded with antimicrobial peptides of epithelial cell origin, including
cathelicidin-37 and β-defensin-2. Thereby, exposure of sporozoites from Cryptosporidium
parvum to IEC-derived exosomes decreases their infectivity in vitro and ex vivo, which
suggests exosome roles in antimicrobial defense against invading pathogens within the
intestinal mucosa [151].
In addition to exosomes from IECs, DCs also release exosomes with protective, ben-
eficial properties to the host. There is evidence that Schistosoma japonicum is a parasite
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with protective effects against colitis in mice. Although parasite-based therapy has been
suggested as a potential strategy, its effects can be harmful to the host. To overcome this
limitation, administration of exosomes from DCs stimulated with soluble egg antigen from
Schistosoma japonicum was evaluated as an alternative treatment in the DSS-induced colitis
model in mice. The study revealed that exosome-based treatment improves disease and
histological scores, which suggests its potential use as a new therapy tool in IBD [152].
3.4.2. Micro-RNAs Transported Through IEC-Derived EV Modulate the Gut Microbiota
The human gastrointestinal tract is colonized by a diverse microbial community
known as the gut microbiota, which is essential to intestinal homeostasis and human health.
In addition to its contribution to food digestion and nutrient metabolism, the gut micro-
biota plays a fundamental role in host immune system development and in the modulation
of gut barrier and immune responses [153]. Studies on gut microbiota have increased
exponentially in the last few years. From these studies, we have learned that imbalances
in microbiota composition and diversity (dysbiosis) disturb host balanced responses and
contribute to a wide variety of inflammatory, autoimmune, metabolic, and neurological
diseases [154–156]. For instance, there is evidence that microbiota composition is altered in
IBD patients and that bacterial translocation to blood occurs recurrently [157]. To preserve
intestinal homeostasis in such a densely populated environment, elaborated regulatory
networks are required to ensure symbiosis and avoid aberrant responses. Regulation by
miRNAs is among these mechanisms with a relevant role in inter-kingdom communication.
Many studies indicate that microbiota and host miRNAs regulate each other. Gut bacteria
have a great impact on miRNA expression, and host miRNAs shape and regulate gut
microbiota [158–160]. Remarkably, host micro-RNAs in the intestinal lumen are exported
through exosomes, mainly derived from IECs [161]. Currently, the study of fecal miRNAs
is receiving great interest for their potential application as disease markers. In this context,
Liu et al. (2016) reported that miRNAs identified in the gut lumen and feces of mice and
humans are present within EVs, which mainly originate from IECs, goblet cells, and Paneth
cells, with little or no contribution of immune cells. In addition, this study revealed for
the first time that fecal miRNAs shape the gut microbiome [162]. In fact, in silico analysis
revealed that bacterial nucleic acid sequences could be targeted by various human miRNAs
through complementary base pairing. The authors showed that miRNAs could enter
bacteria, interact with nucleic acids, and specifically regulate bacterial growth and gene
expression, although the precise mechanisms governing these effects were not elucidated.
They found specific correlations between certain miRNAs and bacterial species. In par-
ticular, miR-1226-5p promoted growth of Escherichia coli, whereas miR-515-5p stimulated
growth of Fusobacterium nucleatum [162]. The impact of fecal miRNAs on gut microbiota
was evidenced in mice deficient in the endoribonuclease Dicer-dependent miRNA process-
ing enzyme. Mutant mice unable to produce miRNAs by IECs display uncontrolled gut
microbiota and aggravated DSS-induced colitis. These effects were counteracted by fecal
transplantation of miRNAs from wild-type mice [162]. Studies performed in germ-free
mice confirmed the role of fecal miRNAs in shaping gut microbiota. In this model too, the
amount of fecal miRNA was inversely correlated with the abundance of microbes [163].
In addition, this study revealed that depletion of the gut microbiota by antibiotic treatment
also influences fecal miRNA expression, which in turn correlates with the abundance of
specific phyla. Authors found a correlation of miR-141-3p with abundance of the phyla Bac-
teroidetes and Firmicutes, and miR-200a-3p with the phyla Actinobacteria, Bacteroidetes,
Cyanobacteria, Firmicutes, and Proteobacteria. All these findings reveal a hitherto un-
known route by which the gut microbiome is modulated by the host through miRNAs
delivered within EVs released by IECs (Table 1). Moreover, this knowledge suggests that
miRNAs might be used as a therapeutic strategy to manipulate microbiota for the treatment
of dysbiosis-associated diseases.
The regulatory mechanisms of miRNAs described in this review are summarized
in Table 1.
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Table 1. Micro-RNAs transported through EV important in the gut environment.




miR-21 Downregulates expression of occludin and E-cadherinIncreases prostaglandin E2, IL-8, IL-6, TNF-α, ICAM-1, and MPO [67–69]
miR-223 Secreted by mast cell-derived exosomesDownregulates claudin-8, ZO-1, and occluding in IECS [73]
miR-29a Downregulates expression of claudin-1 and NκRFInduces apoptosis by targeting Mcl-1 [77–79]
miR-122 Upregulates EGFR and zonulinDownregulates occludin expression [82,83]
miR-874 Downregulates aquaporin 3, occludin, claudin-1, and mucin-2 [84]
miR-34a/c and
miR-29b-3p
Secreted by MSC-derived exosomes
Improve intestinal barrier function by targeting Snail




Promotes IEC proliferation and wound healing by
targeting LATS1






Secreted by MSC-derived exosomes




Contributes to the pathogenesis of IBD
Promotes Th1 and Th17 responses
Downregulates SOCS1 and increases IL-6 and IL-8 levels




Suppress inflammation by NF-κB signaling pathway




Activates NF-κβ signaling and production of
proinflammatory cytokines
Downregulates NLRP3 inflammasome expression
[141–143]
miR-16 Downregulates adenosine A2a receptor and activatesNF-κB pathway [147]
miR-10a
Decreased in IBD
Its targets, NOD2 and Il-12, are upregulated in IBD
Associated with Th1 and Th17 immune responses
[148]
miR-195a-3p Highly expressed in T reg-derived exosomesInhibits apoptosis by targeting caspase-12 [150]
Regulation of gut
microbiota
miR-1226-5p Promotes growth of Escherichia coli and Fusobacterium nucleatum [162]
miR-515-5p Promotes growth of Fusobacterium nucleatum [162]
miR-141-3p Associated with abundance of phylaBacteroidetes and Firmicutes [163]
miR-200a-3p Associated with abundance of phyla Actinobacteria,Bacteroidetes, Cyanobacteria, Firmicutes, and Proteobacteria [163]
4. Conclusions
Recent knowledge supports the idea that EVs play a relevant role as communication
vehicles, specifically transporting and delivering into recipient cells messenger molecules
including proteins, lipids, DNA, and RNA. Production of EVs and cargo selection depends
on changes in cellular conditions or external stimuli, and consequently, they have a great
impact on physiology and body homeostasis. The intestine is critical in controlling human
health. Epithelial and immune cells of the intestinal mucosa are constantly exposed to
millions of microbes that greatly influence the integrity of intestinal epithelial barrier and
immune function. In this ecosystem, both inter-kingdom and intra-host–cell communi-
cations are key to control microbiota population and avoid exacerbated inflammatory
responses. Host-derived EVs have a relevant role in mediating such interplay, controlling
intestinal homeostasis at various levels, as summarized in Figure 3. Little is known about
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the function of host EVs in controlling gut microbiota, but recent reports point to fecal
miRNAs secreted through EVs released by IECs to the gut lumen as modulators of this
microbial community. Since genetic and environmental factors including diet, stress, drugs,
and dysbiosis affect vesicular cargo, EVs derived from cells of the intestinal mucosa open
opportunities to explore their potential as therapeutic targets or diagnostic biomarkers,
particularly in IBD.
Figure 3. Graphical summary of functions of EVs within the gut environment. EVs derived from IECs and immune
cells of the lamina propria contribute to cell-to-cell communication in the gut and have great impact on the homeosta-
sis/inflammation balance. The scheme summarized the bioactive cargo in EVs that can influence epithelial barrier integrity,
tissue repair, immune responses, control of pathogens, and microbiota shaping.
Author Contributions: Conceptualization, J.B. and L.B.; investigation, N.D.-G., C.C., Y.O.-M., L.B.,
and J.B.; writing—original draft preparation, N.D.-G.; writing—review and editing, L.B. and J.B.;
visualization, N.D.-G., C.C., and Y.O.-M.; supervision, L.B.; project administration, J.B.; funding
acquisition, L.B. and J.B. All authors have read and agreed to the published version of the manuscript.
Funding: This research was funded by Ministerio de Ciencia e Innovación, Gobierno de España,
grant number PID2019-107327RB-100.
Data Availability Statement: Data sharing is not applicable to this article. No new data were created
in this review.
Acknowledgments: We acknowledge Lucille Banham for assistance in preparing the English manuscript.
N. Diaz-Garrido acknowledges her doctoral fellowship from Agencia Nacional de Investigación
y Desarrollo (ANID)/Scholarship Program/DOCTORADO BECAS CHILE /2017—72180379. C.
Cordero acknowledges her doctoral fellowship from Agencia Nacional de Investigación y Desarrollo
(ANID)/Scholarship Program/DOCTORADO BECAS CHILE/2020—72210404. Y. Olivo-Martínez
acknowledges her doctoral fellowship from Ministerio de Ciencia, Tecnología e innovación (Mincien-
cias) COLOMBIA/Scholarship Program/DOCTORADO INTERNATIONAL/2020—860.
Conflicts of Interest: The authors declare no conflict of interest.
References
1. Peterson, L.W.; Artis, D. Intestinal epithelial cells: Regulators of barrier function and immune homeostasis. Nat. Rev. Immunol.
2014, 14, 141–153. [CrossRef] [PubMed]
2. Yáñez-Mó, M.; Siljander, P.R.M.; Andreu, Z.; Zavec, A.B.; Borràs, F.E.; Buzas, E.I.; Buzas, K.; Casal, E.; Cappello, F.;
Carvalho, J.; et al. Biological properties of extracellular vesicles and their physiological functions. J. Extracell. Vesicles 2015, 4,
1–60. [CrossRef] [PubMed]
Int. J. Mol. Sci. 2021, 22, 2213 19 of 25
3. Théry, C.; Witwer, K.W.; Aikawa, E.; Alcaraz, M.J.; Anderson, J.D.; Andriantsitohaina, R.; Antoniou, A.; Arab, T.; Archer, F.;
Atkin-Smith, G.K.; et al. Minimal information for studies of extracellular vesicles 2018 (MISEV2018): A position statement of
the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines. J. Extracell. Vesicles 2018, 7, 1–42.
[CrossRef] [PubMed]
4. Pegtel, D.M.; Gould, S.J. Exosomes. Annu. Rev. Biochem. 2019, 88, 487–514. [CrossRef]
5. Zhang, H.; Freitas, D.; Kim, H.S.; Fabijanic, K.; Li, Z.; Chen, H.; Mark, M.T.; Molina, H.; Martin, A.B.; Bojmar, L.; et al. Identification
of distinct nanoparticles and subsets of extracellular vesicles by asymmetric-flow field-flow fractionation. Nat. Cell Biol. 2018, 20,
332–343. [CrossRef]
6. Barile, L.; Vassalli, G. Exosomes: Therapy delivery tools and biomarkers of diseases. Pharmacol. Ther. 2017, 174, 63–78. [CrossRef]
7. Abels, E.R.; Breakefield, X.O. Introduction to Extracellular Vesicles: Biogenesis, RNA Cargo Selection, Content, Release, and Up-
take. Cell. Mol. Neurobiol. 2016, 36, 301–312. [CrossRef] [PubMed]
8. Sedgwick, A.E.; D’Souza-Schorey, C. The Biology of Extracellular Microvesicles. Traffic 2018, 19, 319–327. [CrossRef] [PubMed]
9. Wolf, P. The Nature and Significance of Platelet Products in Human Plasma. Br. J. Haematol. 1967, 13, 269–288. [CrossRef]
10. Meehan, B.; Rak, J.; Di Vizio, D. Oncosomes—Large and small: What are they, where they came from? J. Extracell Vesicles 2016, 5,
1–2. [CrossRef]
11. Zaborowski, M.P.; Balaj, L.; Breakefield, X.O.; Lai, C.P. Extracellular Vesicles: Composition, Biological Relevance, and Methods of
Study. Bioscience 2015, 65, 783–797. [CrossRef]
12. Caruso, S.; Poon, I.K.H. Apoptotic Cell-Derived Extracellular Vesicles: More Than Just Debris. Front. Immunol. 2018, 9, 1–9.
[CrossRef]
13. Mathieu, M.; Martin-Jaular, L.; Lavieu, G.; Théry, C. Specificities of secretion and uptake of exosomes and other extracellular
vesicles for cell-to-cell communication. Nat. Cell Biol. 2019, 21, 9–17. [CrossRef] [PubMed]
14. Juan, T.; Fürthauer, M. Biogenesis and function of ESCRT-dependent extracellular vesicles. Semin. Cell Dev. Biol. 2018, 74, 66–77.
[CrossRef] [PubMed]
15. Kajimoto, T.; Okada, T.; Miya, S.; Zhang, L.; Nakamura, S. Ongoing activation of sphingosine 1-phosphate receptors mediates
maturation of exosomal multivesicular endosomes. Nat. Commun. 2013, 4, 2712. [CrossRef]
16. Colombo, M.; Raposo, G.; Théry, C. Biogenesis, Secretion, and Intercellular Interactions of Exosomes and Other Extracellular
Vesicles. Annu. Rev. Cell Dev. Biol. 2014, 30. [CrossRef]
17. Van Niel, G.; Charrin, S.; Simoes, S.; Romao, M.; Rochin, L.; Saftig, P.; Marks, M.S.; Rubinstein, E.; Raposo, G. The tetraspanin
CD63 regulates ESCRT-independent and -dependent endosomal sorting during melanogenesis. Dev. Cell 2011, 21, 708–721.
[CrossRef]
18. Nabhan, J.F.; Hu, R.; Oh, R.S.; Cohen, S.N.; Lu, Q. Formation and release of arrestin domain-containing protein 1-mediated
microvesicles (ARMMs) at plasma membrane by recruitment of TSG101 protein. Proc. Natl. Acad. Sci. USA 2012, 109, 4146–4151.
[CrossRef] [PubMed]
19. Meldolesi, J. Exosomes and Ectosomes in Intercellular Communication. Curr. Biol. 2018, 28, R435–R444. [CrossRef]
20. Van Niel, G.; D’Angelo, G.; Raposo, G. Shedding Light on the Cell Biology of Extracellular Vesicles. Nat. Rev. Mol. Cell Biol. 2018,
19. [CrossRef]
21. Kowal, J.; Tkach, M.; Théry, C. Biogenesis and Secretion of Exosomes. Curr. Opin. Cell Biol. 2014, 29. [CrossRef] [PubMed]
22. French, K.C.; Antonyak, M.A.; Cerione, R.A. Extracellular vesicle docking at the cellular port: Extracellular vesicle binding and
uptake. Semin. Cell Dev. Biol. 2017, 67, 48–55. [CrossRef]
23. Mathivanan, S.; Fahner, C.J.; Reid, G.E.; Simpson, R.J. ExoCarta 2012: Database of exosomal proteins, RNA and lipids.
Nucleic Acids Res. 2012, 40, D1241–D1244. [CrossRef]
24. Kalra, H.; Simpson, R.J.; Ji, H.; Aikawa, E.; Altevogt, P.; Askenase, P.; Bond, V.C.; Borras, F.E.; Breakefield, X.; Budnik, V.; et al.
Vesiclepedia: A compendium for extracellular vesicles with continuous community annotation. PLoS Biol. 2012, 10, e1001450.
[CrossRef] [PubMed]
25. Kim, D.K.; Kang, B.; Kim, O.Y.; Choi, D.S.; Lee, J.; Kim, S.R.; Go, G.; Yoon, Y.J.; Kim, J.H.; Jang, S.C.; et al. EVpedia: An integrated
database of high-throughput data for systemic analyses of extracellular vesicles. J. Extracell Vesicles 2013, 2. [CrossRef]
26. Choi, D.S.; Kim, D.K.; Kim, Y.K.; Gho, Y.S. Proteomics of extracellular vesicles: Exosomes and ectosomes. Mass Spectrom Rev. 2015,
34, 474–490. [CrossRef] [PubMed]
27. Vagner, T.; Chin, A.; Mariscal, J.; Bannykh, S.; Engman, D.M.; Di Vizio, D. Protein Composition Reflects Extracellular Vesicle
Heterogeneity. Proteomics 2019, 19, e1800167. [CrossRef]
28. Haraszti, R.A.; Didiot, M.C.; Sapp, E.; Leszyk, J.; Shaffer, S.A.; Rockwell, H.E.; Gao, F.; Narain, N.R.; DiFiglia, M.;
Kiebish, M.A.; et al. High-resolution proteomic and lipidomic analysis of exosomes and microvesicles from different cell sources.
J. Extracell Vesicles 2016, 5, 32570. [CrossRef]
29. Morita, E.; Sandrin, V.; Chung, H.Y.; Morham, S.G.; Gygi, S.P.; Rodesch, C.K.; Sundquist, W.I. Human ESCRT and ALIX proteins
interact with proteins of the midbody and function in cytokinesis. EMBO J. 2007, 26, 4215–4227. [CrossRef] [PubMed]
30. Théry, C.; Boussac, M.; Véron, P.; Ricciardi-Castagnoli, P.; Raposo, G.; Garin, J.; Amigorena, S. Proteomic analysis of dendritic
cell-derived exosomes: A secreted subcellular compartment distinct from apoptotic vesicles. J. Immunol. 2001, 166, 7309–7318.
[CrossRef]
Int. J. Mol. Sci. 2021, 22, 2213 20 of 25
31. Kowal, J.; Arras, G.; Colombo, M.; Jouve, M.; Morath, J.P.; Primdal-Bengtson, B.; Dingli, F.; Loew, D.; Tkach, M.; Thery, C.
Proteomic comparison defines novel markers to characterize heterogeneous populations of extracellular vesicle subtypes.
Proc. Natl. Acad. Sci. USA 2016, 113, E968–E977. [CrossRef]
32. Gonzalez-Begne, M.; Lu, B.; Han, X.; Hagen, F.K.; Hand, A.R.; Melvin, J.E.; Yates, J.R. Proteomic analysis of human parotid
gland exosomes by multidimensional protein identification technology (MudPIT). J. Proteome Res. 2009, 8, 1304–1314. [CrossRef]
[PubMed]
33. Skotland, T.; Sandvig, K.; Llorente, A. Lipids in exosomes: Current knowledge and the way forward. Prog. Lipid Res. 2017, 66,
30–41. [CrossRef]
34. Skotland, T.; Sagini, K.; Sandvig, K.; Llorente, A. An emerging focus on lipids in extracellular vesicles. Adv. Drug Deliv. Rev. 2020.
[CrossRef] [PubMed]
35. Kreimer, S.; Belov, A.M.; Ghiran, I.; Murthy, S.K.; Frank, D.A.; Ivanov, A.R. Mass-spectrometry-based molecular characterization
of extracellular vesicles: Lipidomics and proteomics. J. Proteome Res. 2015, 14, 2367–2384. [CrossRef]
36. Chen, S.; Datta-Chaudhuri, A.; Deme, P.; Dickens, A.; Dastgheyb, R.; Bhargava, P.; Bi, H.; Haughey, N.J. Lipidomic characterization
of extracellular vesicles in human serum. J. Circ. Biomark. 2019, 8, 1849454419879848. [CrossRef]
37. Skotland, T.; Hessvik, N.P.; Sandvig, K.; Llorente, A. Exosomal lipid composition and the role of ether lipids and phosphoinositides
in exosome biology. J. Lipid Res. 2019, 60, 9–18. [CrossRef] [PubMed]
38. Muralidharan-Chari, V.; Clancy, J.; Plou, C.; Romao, M.; Chavrier, P.; Raposo, G.; D’Souza-Schorey, C. ARF6-regulated shedding
of tumor cell-derived plasma membrane microvesicles. Curr. Biol. 2009, 19, 1875–1885. [CrossRef] [PubMed]
39. Kawamura, Y.; Yamamoto, Y.; Sato, T.-A.; Ochiya, T. Extracellular vesicles as trans-genomic agents: Emerging roles in disease and
evolution. Cancer Sci. 2017, 108, 824–830. [CrossRef]
40. Turchinovich, A.; Drapkina, O.; Tonevitsky, A. Transcriptome of Extracellular Vesicles: State-of-the-Art. Front. Immunol. 2019, 10.
[CrossRef] [PubMed]
41. Zhang, J.; Li, S.; Li, L.; Li, M.; Guo, C.; Yao, J.; Mi, S. Exosome and exosomal microRNA: Trafficking, sorting, and function.
Genom. Proteom. Bioinform. 2015, 13, 17–24. [CrossRef]
42. Fabbri, M.; Paone, A.; Calore, F.; Galli, R.; Gaudio, E.; Santhanam, R.; Lovat, F.; Fadda, P.; Mao, C.; Nuovo, G.J.; et al. MicroRNAs
bind to Toll-like receptors to induce prometastatic inflammatory response. Proc. Natl. Acad. Sci. USA 2012, 109, E2110–E2116.
[CrossRef]
43. Tahamtan, A.; Teymoori-Rad, M.; Nakstad, B.; Salimi, V. Anti-Inflammatory MicroRNAs and Their Potential for Inflammatory
Diseases Treatment. Front. Immunol. 2018, 9, 1377. [CrossRef] [PubMed]
44. Liu, T.; Zhang, Q.; Zhang, J.; Li, C.; Miao, Y.R.; Lei, Q.; Li, Q.; Guo, A.Y. EVmiRNA: A database of miRNA profiling in extracellular
vesicles. Nucleic Acids Res. 2019, 47, D89–D93. [CrossRef] [PubMed]
45. Mills, J.; Capece, M.; Cocucci, E.; Tessari, A.; Palmieri, D. Cancer-Derived Extracellular Vesicle-Associated MicroRNAs in
Intercellular Communication: One Cell’s Trash Is Another Cell’s Treasure. Int. J. Mol. Sci. 2019, 20, 6109. [CrossRef]
46. Valter, M.; Verstockt, S.; Finalet Ferreiro, J.A.; Cleynen, I. Extracellular vesicles in inflammatory bowel disease: Small particles, big
players. J. Crohns Colitis 2020. [CrossRef] [PubMed]
47. Zhou, G.X.; Liu, Z.J. Potential Roles of Neutrophils in Regulating Intestinal Mucosal Inflammation of Inflammatory Bowel
Disease. J. Dig. Dis. 2017, 18. [CrossRef]
48. Landy, J.; Ronde, E.; English, N.; Clark, S.K.; Hart, A.L.; Knight, S.C.; Ciclitira, P.J.; Al-Hassi, H.O. Tight junctions in inflammatory
bowel diseases and inflammatory bowel disease associated colorectal cancer. World J. Gastroenterol. 2016, 22, 3117–3126. [CrossRef]
49. Kucharzik, T.; Walsh, S.V.; Chen, J.; Parkos, C.A.; Nusrat, A. Neutrophil Transmigration in Inflammatory Bowel Disease Is
Associated with Differential Expression of Epithelial Intercellular Junction Proteins. Am. J. Pathol. 2001, 159, 2001–2009. [CrossRef]
50. Rossaint, J.; Kühne, K.; Skupski, J.; Van Aken, H.; Looney, M.R.; Hidalgo, A.; Zarbock, A. Directed transport of neutrophil-derived
extracellular vesicles enables platelet-mediated innate immune response. Nat. Commun. 2016, 7. [CrossRef]
51. Butin-Israeli, V.; Houser, M.C.; Feng, M.; Thorp, E.B.; Nusrat, A.; Parkos, C.A.; Sumagin, R. Deposition of Microparticles
by Neutrophils Onto Inflamed Epithelium: A New Mechanism to Disrupt Epithelial Intercellular Adhesions and Promote
Transepithelial Migration. FASEB J. 2016, 30. [CrossRef]
52. Ungewiß, H.; Vielmuth, F.; Suzuki, S.T.; Maiser, A.; Harz, H.; Leonhardt, H.; Kugelmann, D.; Schlegel, N.; Waschke, J. Desmoglein
2 regulates the intestinal epithelial barrier via p38 mitogen-activated protein kinase. Sci. Rep. 2017, 7. [CrossRef]
53. Madrigal-Matute, J.; Lindholt, J.S.; Fernandez-Garcia, C.E.; Benito-Martin, A.; Burillo, E.; Zalba, G.; Beloqui, O.; Llamas-Granda, P.;
Ortiz, A.; Egido, J.; et al. Galectin-3, a Biomarker Linking Oxidative Stress and Inflammation With the Clinical Outcomes of
Patients With Atherothrombosis. J. Am. Heart Assoc. 2014, 3. [CrossRef]
54. Jiang, K.; Rankin, C.R.; Nava, P.; Sumagin, R.; Kamekura, R.; Stowell, S.R.; Feng, M.; Parkos, C.A.; Nusrat, A. Galectin-3 Regulates
Desmoglein-2 and Intestinal Epithelial Intercellular Adhesion. J. Biol. Chem. 2014, 289, 10510–10517. [CrossRef]
55. Eken, C.; Sadallah, S.; Martin, P.J.; Treves, S.; Schifferli, J.A. Ectosomes of polymorphonuclear neutrophils activate multiple
signaling pathways in macrophages. Immunobiology 2013, 218, 382–392. [CrossRef]
56. Mitsuhashi, S.; Feldbrügge, L.; Csizmadia, E.; Mitsuhashi, M.; Robson, S.C.; Moss, A.C. Luminal Extracellular Vesicles (EVs) in
Inflammatory Bowel Disease (IBD) Exhibit Pro-Inflammatory Effects on Epithelial Cells and Macrophages. Inflamm. Bowel Dis.
2016, 22, 1587–1595. [CrossRef]
Int. J. Mol. Sci. 2021, 22, 2213 21 of 25
57. Al-Sadi, R.; Guo, S.; Ye, D.; Ma, T.Y. TNF-α Modulation of Intestinal Epithelial Tight Junction Barrier Is Regulated by ERK1/2
Activation of Elk-1. Am. J. Pathol. 2013, 183, 1871–1884. [CrossRef] [PubMed]
58. Robertson, C.; Booth, S.A.; Beniac, D.R.; Coulthart, M.B.; Booth, T.F.; McNicol, A. Cellular prion protein is released on exosomes
from activated platelets. Blood 2006, 107, 3907–3911. [CrossRef]
59. Petit, C.S.; Barreau, F.; Besnier, L.; Gandille, P.; Riveau, B.; Chateau, D.; Roy, M.; Berrebi, D.; Svrcek, M.; Cardot, P.; et al.
Requirement of cellular prion protein for intestinal barrier function and mislocalization in patients with inflammatory bowel
disease. Gastroenterology 2012, 143, 122–132.e15. [CrossRef] [PubMed]
60. Moein, S.; Vaghari-Tabari, M.; Qujeq, D.; Majidinia, M.; Nabavi, S.M.; Yousefi, B. MiRNAs and Inflammatory Bowel Disease: An
Interesting New Story. J. Cell. Physiol. 2019, 234. [CrossRef]
61. Chen, P.; Zhou, G.; Lin, J.; Li, L.; Zeng, Z.; Chen, M.; Zhang, S. Serum Biomarkers for Inflammatory Bowel Disease. Front. Med.
2020, 7, 123. [CrossRef] [PubMed]
62. Arroyo, J.D.; Chevillet, J.R.; Kroh, E.M.; Ruf, I.K.; Pritchard, C.C.; Gibson, D.F.; Mitchell, P.S.; Bennett, C.F.; Pogosova-Agadjanyan,
E.L.; Stirewalt, D.L.; et al. Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human
plasma. Proc. Natl. Acad. Sci. USA 2011, 108, 5003–5008. [CrossRef] [PubMed]
63. Vickers, K.C.; Palmisano, B.T.; Shoucri, B.M.; Shamburek, R.D.; Remaley, A.T. MicroRNAs are transported in plasma and delivered
to recipient cells by high-density lipoproteins. Nat. Cell Biol. 2011, 13, 423–433. [CrossRef]
64. Ludwig, K.; Fassan, M.; Mescoli, C.; Pizzi, M.; Balistreri, M.; Albertoni, L.; Pucciarelli, S.; Scarpa, M.; Sturniolo, G.C.;
Angriman, I.; et al. PDCD4/miR-21 dysregulation in inflammatory bowel disease-associated carcinogenesis. Virchows Arch.
2013, 462, 57–63. [CrossRef]
65. Wu, F.; Zikusoka, M.; Trindade, A.; Dassopoulos, T.; Harris, M.L.; Bayless, T.M.; Brant, S.R.; Chakravarti, S.; Kwon, J.H.
MicroRNAs are differentially expressed in ulcerative colitis and alter expression of macrophage inflammatory peptide-2 alpha.
Gastroenterology 2008, 135, 1624–1635.e24. [CrossRef] [PubMed]
66. Bakirtzi, K.; Man Law, I.K.; Fang, K.; Iliopoulos, D.; Pothoulakis, C. MiR-21 in Substance P-induced exosomes promotes cell
proliferation and migration in human colonic epithelial cells. Am. J. Physiol. Gastrointest. Liver Physiol. 2019, 317, G802–G810.
[CrossRef] [PubMed]
67. Zhang, L.; Shen, J.; Cheng, J.; Fan, X. MicroRNA-21 regulates intestinal epithelial tight junction permeability. Cell Biochem. Funct.
2015, 33, 235–240. [CrossRef] [PubMed]
68. Zhang, L.; Zhang, F.; He, D.K.; Fan, X.M.; Shen, J. MicroRNA-21 is upregulated during intestinal barrier dysfunction induced by
ischemia reperfusion. Kaohsiung J. Med. Sci. 2018, 34, 556–563. [CrossRef]
69. Shi, C.; Liang, Y.; Yang, J.; Xia, Y.; Chen, H.; Han, H.; Yang, Y.; Wu, W.; Gao, R.; Qin, H. MicroRNA-21 knockout improve the
survival rate in DSS induced fatal colitis through protecting against inflammation and tissue injury. PLoS ONE 2013, 8, e66814.
[CrossRef] [PubMed]
70. Yuan, X.; Berg, N.; Woong Lee, J.; Le, T.T.; Neudecker, V.; Jing, N.; Eltzschig, H. MicroRNA miR-223 as Regulator of Innate
Immunity. J. Leukoc. Biol. 2018, 104, 515–524. [CrossRef]
71. Wang, H.; Zhang, S.; Yu, Q.; Yang, G.; Guo, J.; Li, M.; Zeng, Z.; He, Y.; Chen, B.; Chen, M. Circulating MicroRNA223 is a New
Biomarker for Inflammatory Bowel Disease. Medicine 2016, 95, e2703. [CrossRef] [PubMed]
72. Wang, H.; Chao, K.; Ng, S.C.; Bai, A.H.; Yu, Q.; Yu, J.; Li, M.; Cui, Y.; Chen, M.; Hu, J.-F.; et al. Pro-inflammatory miR-223 mediates
the cross-talk between the IL23 pathway and the intestinal barrier in inflammatory bowel disease. Genome Biol. 2016, 17, 58.
[CrossRef] [PubMed]
73. Li, M.; Zhao, J.; Cao, M.; Liu, R.; Chen, G.; Li, S.; Xie, Y.; Xie, J.; Cheng, Y.; Huang, L.; et al. Mast cells-derived MiR-223 destroys
intestinal barrier function by inhibition of CLDN8 expression in intestinal epithelial cells. Biol. Res. 2020, 53. [CrossRef] [PubMed]
74. Zhao, Y.J.; Song, X.; Niu, L.; Tang, Y.; Song, X.; Xie, L. Circulating Exosomal miR-150-5p and miR-99b-5p as Diagnostic Biomarkers
for Colorectal Cancer. Front. Oncol. 2019, 9, 1129. [CrossRef] [PubMed]
75. Sun, L.; Liu, X.; Pan, B.; Hu, X.; Zhu, Y.; Su, Y.; Guo, Z.; Zhang, G.; Xu, M.; Xu, X.; et al. Serum exosomal miR-122 as a potential
diagnostic and prognostic biomarker of colorectal cancer with liver metastasis. J. Cancer 2020, 11, 630–637. [CrossRef]
76. Zhang, N.; Zhang, P.-P.; Huang, J.-J.; Wang, Z.-Y.; Zhang, Z.-H.; Yuan, J.-Z.; Ma, E.-M.; Liu, X.; Bai, J. Reduced serum exosomal
miR-874 expression predicts poor prognosis in colorectal cancer. Eur. Rev. Med. Pharmacol. Sci. 2020, 24, 664–672. [CrossRef]
77. Zhou, Q.; Souba, W.W.; Croce, C.M.; Verne, G.N. MicroRNA-29a Regulates Intestinal Membrane Permeability in Patients with
Irritable Bowel Syndrome. Gut 2010, 59, 775–784. [CrossRef] [PubMed]
78. Zhou, Q.; Costinean, S.; Croce, C.M.; Brasier, A.R.; Merwat, S.; Larson, S.A.; Basra, S.; Verne, G.N. MicroRNA 29 Targets Nuclear
Factor-κB–Repressing Factor and Claudin 1 to Increase Intestinal Permeability. Gastroenterology 2015, 148, 158–169.e8. [CrossRef]
79. Lv, B.; Liu, Z.; Wang, S.; Liu, F.; Yang, X.; Hou, J.; Hou, Z.; Chen, B. miR-29a promotes intestinal epithelial apoptosis in ulcerative
colitis by down-regulating Mcl-1. Int. J. Clin. Exp. Pathol. 2014, 7, 8542–8552.
80. Lindenbergh, M.F.S.; Stoorvogel, W. Antigen Presentation by Extracellular Vesicles from Professional Antigen-Presenting Cells.
Annu. Rev. Immunol. 2018, 36. [CrossRef]
81. Nolte-’t Hoen, E.N.; Buschow, S.I.; Anderton, S.M.; Stoorvogel, W.; Wauben, M.H. Activated T cells recruit exosomes secreted by
dendritic cells via LFA-1. Blood 2009, 113, 1977–1981. [CrossRef] [PubMed]
82. Zhang, B.; Tian, Y.; Jiang, P.; Jiang, Y.; Li, C.; Liu, T.; Zhou, R.; Yang, N.; Zhou, X.; Liu, Z. MicroRNA-122a Regulates Zonulin by
Targeting EGFR in Intestinal Epithelial Dysfunction. Cell Physiol. Biochem. 2017, 42, 848–858. [CrossRef]
Int. J. Mol. Sci. 2021, 22, 2213 22 of 25
83. Ye, D.; Guo, S.; Al-Sadi, R.; Ma, T.Y. MicroRNA regulation of intestinal epithelial tight junction permeability. Gastroenterology
2011, 141, 1323–1333. [CrossRef]
84. Zhi, X.; Tao, J.; Li, Z.; Jiang, B.; Feng, J.; Yang, L.; Xu, H.; Xu, Z. MiR-874 promotes intestinal barrier dysfunction through targeting
AQP3 following intestinal ischemic injury. FEBS Lett. 2014, 588, 757–763. [CrossRef]
85. Leoni, G.; Neumann, P.A.; Sumagin, R.; Denning, T.L.; Nusrat, A. Wound repair: Role of immune-epithelial interactions.
Mucosal Immunol. 2015, 8, 959–968. [CrossRef] [PubMed]
86. Babbin, B.A.; Laukoetter, M.G.; Nava, P.; Koch, S.; Lee, W.Y.; Capaldo, C.T.; Peatman, E.; Severson, E.A.; Flower, R.J.;
Perretti, M.; et al. Annexin A1 regulates intestinal mucosal injury, inflammation, and repair. J. Immunol. 2008, 181, 5035–5044.
[CrossRef] [PubMed]
87. Leoni, G.; Alam, A.; Neumann, P.A.; Lambeth, J.D.; Cheng, G.; McCoy, J.; Hilgarth, R.S.; Kundu, K.; Murthy, N.; Kusters, D.; et al.
Annexin A1, formyl peptide receptor, and NOX1 orchestrate epithelial repair. J. Clin. Investig. 2013, 123, 443–454. [CrossRef]
[PubMed]
88. Leoni, G.; Neumann, P.A.; Kamaly, N.; Quiros, M.; Nishio, H.; Jones, H.R.; Sumagin, R.; Hilgarth, R.S.; Alam, A.; Fredman, G.; et al.
Annexin A1-containing extracellular vesicles and polymeric nanoparticles promote epithelial wound repair. J. Clin. Investig. 2015,
125, 1215–1227. [CrossRef]
89. Dalli, J.; Norling, L.V.; Renshaw, D.; Cooper, D.; Leung, K.Y.; Perretti, M. Annexin 1 mediates the rapid anti-inflammatory effects
of neutrophil-derived microparticles. Blood 2008, 112, 2512–2519. [CrossRef]
90. Zhang, X.; Deeke, S.A.; Ning, Z.; Starr, A.E.; Butcher, J.; Li, J.; Mayne, J.; Cheng, K.; Liao, B.; Li, L.; et al. Metaproteomics
reveals associations between microbiome and intestinal extracellular vesicle proteins in pediatric inflammatory bowel disease.
Nat. Commun. 2018, 9, 2873. [CrossRef]
91. Davies, M.J. Myeloperoxidase-derived oxidation: Mechanisms of biological damage and its prevention. J. Clin. Biochem. Nutr.
2011, 48, 8–19. [CrossRef]
92. Slater, T.W.; Finkielsztein, A.; Mascarenhas, L.A.; Mehl, L.C.; Butin-Israeli, V.; Sumagin, R. Neutrophil Microparticles Deliver
Active Myeloperoxidase to Injured Mucosa to Inhibit Epithelial Wound Healing. J. Immunol. 2017, 198, 2886–2897. [CrossRef]
[PubMed]
93. Hong, C.W. Extracellular Vesicles of Neutrophils. Immune Netw. 2018, 18, e43. [CrossRef]
94. Pitanga, T.N.; de Aragão França, L.; Rocha, V.C.; Meirelles, T.; Borges, V.M.; Gonçalves, M.S.; Pontes-de-Carvalho, L.C.;
Noronha-Dutra, A.A.; dos-Santos, W.L. Neutrophil-derived microparticles induce myeloperoxidase-mediated damage of vascular
endothelial cells. BMC Cell Biol. 2014, 15, 21. [CrossRef]
95. Deng, F.; Yan, J.; Lu, J.; Luo, M.; Xia, P.; Liu, S.; Wang, X.; Zhi, F.; Liu, D. M2 macrophage-derived exosomal-miR-590-3p attenuates
DSS-induced mucosal damage and promotes epithelial repair via the LATS1/YAP/β-catenin signalling axis. J. Crohns Colitis 2020.
[CrossRef]
96. Bainbridge, P. Wound healing and the role of fibroblasts. J. Wound Care 2013, 22, 407–408, 410–412. [CrossRef]
97. Borges, F.T.; Melo, S.A.; Özdemir, B.C.; Kato, N.; Revuelta, I.; Miller, C.A.; Gattone, V.H.; LeBleu, V.S.; Kalluri, R. TGF-β1–
Containing Exosomes from Injured Epithelial Cells Activate Fibroblasts to Initiate Tissue Regenerative Responses and Fibrosis.
J. Am. Soc. Nephrol. 2013, 24, 385–392. [CrossRef] [PubMed]
98. Luga, V.; Zhang, L.; Viloria-Petit, A.M.; Ogunjimi, A.A.; Inanlou, M.R.; Chiu, E.; Buchanan, M.; Hosein, A.N.; Basik, M.; Wrana, J.L.
Exosomes mediate stromal mobilization of autocrine Wnt-PCP signaling in breast cancer cell migration. Cell 2012, 151, 1542–1556.
[CrossRef] [PubMed]
99. Gregorieff, A.; Pinto, D.; Begthel, H.; Destrée, O.; Kielman, M.; Clevers, H. Expression pattern of Wnt signaling components in
the adult intestine. Gastroenterology 2005, 129, 626–638. [CrossRef] [PubMed]
100. Miyoshi, H. Wnt-expressing cells in the intestines: Guides for tissue remodeling. J. Biochem. 2017, 161, 19–25. [CrossRef]
101. Harada, T.; Yamamoto, H.; Kishida, S.; Kishida, M.; Awada, C.; Takao, T.; Kikuchi, A. Wnt5b-associated exosomes promote cancer
cell migration and proliferation. Cancer Sci. 2017, 108, 42–52. [CrossRef]
102. Saha, S.; Aranda, E.; Hayakawa, Y.; Bhanja, P.; Atay, S.; Brodin, N.P.; Li, J.; Asfaha, S.; Liu, L.; Tailor, Y.; et al. Macrophage-derived
extracellular vesicle-packaged WNTs rescue intestinal stem cells and enhance survival after radiation injury. Nat. Commun. 2016,
7, 13096. [CrossRef]
103. Oh, H.H.; Joo, Y.E. Novel biomarkers for the diagnosis and prognosis of colorectal cancer. Intest. Res. 2020, 18, 168–183. [CrossRef]
104. Williams, B.B.; Tebbutt, N.C.; Buchert, M.; Putoczki, T.L.; Doggett, K.; Bao, S.; Johnstone, C.N.; Masson, F.; Hollande, F.;
Burgess, A.W.; et al. Glycoprotein A33 deficiency: A new mouse model of impaired intestinal epithelial barrier function and
inflammatory disease. Dis. Model. Mech. 2015, 8, 805–815. [CrossRef]
105. Pereira-Fantini, P.M.; Judd, L.M.; Kalantzis, A.; Peterson, A.; Ernst, M.; Heath, J.K.; Giraud, A.S. A33 antigen-deficient mice have
defective colonic mucosal repair. Inflamm. Bowel Dis. 2010, 16, 604–612. [CrossRef]
106. Lin, X.P.; Almqvist, N.; Telemo, E. Human small intestinal epithelial cells constitutively express the key elements for antigen
processing and the production of exosomes. Blood Cells Mol. Dis. 2005, 35, 122–128. [CrossRef] [PubMed]
107. Van Niel, G.; Raposo, G.; Candalh, C.; Boussac, M.; Hershberg, R.; Cerf-Bensussan, N.; Heyman, M. Intestinal epithelial cells
secrete exosome-like vesicles. Gastroenterology 2001, 121, 337–349. [CrossRef]
Int. J. Mol. Sci. 2021, 22, 2213 23 of 25
108. Van Niel, G.; Mallegol, J.; Bevilacqua, C.; Candalh, C.; Brugière, S.; Tomaskovic-Crook, E.; Heath, J.K.; Cerf-Bensussan, N.;
Heyman, M. Intestinal epithelial exosomes carry MHC class II/peptides able to inform the immune system in mice. Gut 2003,
52(12), 1690–1697. [CrossRef]
109. Mallegol, J.; Van Niel, G.; Lebreton, C.; Lepelletier, Y.; Candalh, C.; Dugave, C.; Heath, J.K.; Raposo, G.; Cerf-Bensussan, N.;
Heyman, M. T84-intestinal epithelial exosomes bear MHC class II/peptide complexes potentiating antigen presentation by
dendritic cells. Gastroenterology 2007, 132, 1866–1876. [CrossRef] [PubMed]
110. Mallegol, J.; van Niel, G.; Heyman, M. Phenotypic and Functional Characterization of Intestinal Epithelial Exosomes. Blood Cells.
Mol. Dis. 2005, 35. [CrossRef] [PubMed]
111. Chen, X.; Song, C.H.; Feng, B.S.; Li, T.L.; Li, P.; Zheng, P.Y.; Chen, X.M.; Xing, Z.; Yang, P.C. Intestinal epithelial cell-derived integrin
αβ6 plays an important role in the induction of regulatory T cells and inhibits an antigen-specific Th2 response. J. Leukoc. Biol.
2011, 90, 751–759. [CrossRef] [PubMed]
112. Jiang, L.; Shen, Y.; Guo, D.; Yang, D.; Liu, J.; Fei, X.; Yang, Y.; Zhang, B.; Lin, Z.; Yang, F.; et al. EpCAM-dependent extracellular
vesicles from intestinal epithelial cells maintain intestinal tract immune balance. Nat. Commun. 2016, 7, 13045. [CrossRef]
113. Kojima, M.; Costantini, T.W.; Eliceiri, B.P.; Chan, T.W.; Baird, A.; Coimbra, R. Gut epithelial cell-derived exosomes trigger
posttrauma immune dysfunction. J. Trauma Acute Care Surg. 2018, 84, 257–264. [CrossRef] [PubMed]
114. Thery, C.; Duban, L.; Segura, E.; Veron, P.; Lantz, O.; Amigorena, S. Indirect activation of naive CD4+ T cells by dendritic
cell-derived exosomes. Nat. Immunol. 2002, 3, 1156–1162. [CrossRef] [PubMed]
115. Segura, E.; Nicco, C.; Lombard, B.; Véron, P.; Raposo, G.; Batteux, F.; Amigorena, S.; Théry, C. ICAM-1 on exosomes from mature
dendritic cells is critical for efficient naive T-cell priming. Blood 2005, 106, 216–223. [CrossRef] [PubMed]
116. Oksvold, M.P.; Neurauter, A.; Pedersen, K.W. Magnetic bead-based isolation of exosomes. Methods Mol. Biol. 2015, 1218, 465–481.
[CrossRef]
117. Tkach, M.; Kowal, J.; Zucchetti, A.E.; Enserink, L.; Jouve, M.; Lankar, D.; Saitakis, M.; Martin-Jaular, L.; Thery, C. Qualitative
differences in T-cell activation by dendritic cell-derived extracellular vesicle subtypes. EMBO J. 2017, 36, 3012–3028. [CrossRef]
118. Wang, Y.; Tian, J.; Tang, X.; Rui, K.; Tian, X.; Ma, J.; Ma, B.; Xu, H.; Lu, L.; Wang, S. Exosomes released by granulocytic
myeloid-derived suppressor cells attenuate DSS-induced colitis in mice. Oncotarget 2016, 7, 15356–15368. [CrossRef]
119. Wong, W.-Y.; Lee, M.M.-L.; Chan, B.D.; Kam, R.K.-T.; Zhang, G.; Lu, A.-P.; Tai, W.C.-S. Proteomic profiling of dextran sulfate
sodium induced acute ulcerative colitis mice serum exosomes and their immunomodulatory impact on macrophages. Proteomics
2016, 16, 1131–1145. [CrossRef]
120. Eken, C.; Gasser, O.; Zenhaeusern, G.; Oehri, I.; Hess, C.; Schifferli, J.A. Polymorphonuclear neutrophil-derived ectosomes
interfere with the maturation of monocyte-derived dendritic cells. J. Immunol. 2008, 180, 817–824. [CrossRef]
121. Dalli, J.; Serhan, C.N. Specific lipid mediator signatures of human phagocytes: Microparticles stimulate macrophage efferocytosis
and pro-resolving mediators. Blood 2012, 120, e60–e72. [CrossRef] [PubMed]
122. Esser, J.; Gehrmann, U.; D’Alexandri, F.L.; Hidalgo-Estévez, A.M.; Wheelock, C.E.; Scheynius, A.; Gabrielsson, S.; Rådmark, O.
Exosomes from human macrophages and dendritic cells contain enzymes for leukotriene biosynthesis and promote granulocyte
migration. J. Allergy Clin. Immunol. 2010, 126, 1032–1040. [CrossRef] [PubMed]
123. Butin-Israeli, V.; Bui, T.M.; Wiesolek, H.L.; Mascarenhas, L.; Lee, J.J.; Mehl, L.C.; Knutson, K.R.; Adam, S.A.; Goldman, R.D.;
Beyder, A.; et al. Neutrophil-induced genomic instability impedes resolution of inflammation and wound healing. J. Clin. Investig.
2019, 129, 712–726. [CrossRef] [PubMed]
124. Harrell, C.R.; Jovicic, N.; Djonov, V.; Arsenijevic, N.; Volarevic, V. Mesenchymal Stem Cell-Derived Exosomes and Other
Extracellular Vesicles as New Remedies in the Therapy of Inflammatory Diseases. Cells 2019, 8, 1605. [CrossRef]
125. Wang, G.; Yuan, J.; Cai, X.; Xu, Z.; Wang, J.; Ocansey, D.K.W.; Yan, Y.; Qian, H.; Zhang, X.; Xu, W.; et al. HucMSC-exosomes
carrying miR-326 inhibit neddylation to relieve inflammatory bowel disease in mice. Clin. Transl. Med. 2020, 10, e113. [CrossRef]
[PubMed]
126. Liu, H.; Liang, Z.; Wang, F.; Zhou, C.; Zheng, X.; Hu, T.; He, X.; Wu, X.; Lan, P. Exosomes from mesenchymal stromal cells reduce
murine colonic inflammation via a macrophage-dependent mechanism. JCI Insight 2019, 4. [CrossRef]
127. Yang, J.; Liu, X.-X.; Fan, H.; Tang, Q.; Shou, Z.-X.; Zuo, D.-M.; Zou, Z.; Xu, M.; Chen, Q.-Y.; Peng, Y.; et al. Extracellular Vesicles
Derived from Bone Marrow Mesenchymal Stem Cells Protect against Experimental Colitis via Attenuating Colon Inflammation,
Oxidative Stress and Apoptosis. PLoS ONE 2015, 10, e0140551. [CrossRef]
128. Mao, F.; Wu, Y.; Tang, X.; Kang, J.; Zhang, B.; Yan, Y.; Qian, H.; Zhang, X.; Xu, W. Exosomes Derived from Human Umbilical Cord
Mesenchymal Stem Cells Relieve Inflammatory Bowel Disease in Mice. Biomed. Res. Int. 2017, 2017, 5356760. [CrossRef]
129. Cao, L.; Xu, H.; Wang, G.; Liu, M.; Tian, D.; Yuan, Z. Extracellular vesicles derived from bone marrow mesenchymal stem cells
attenuate dextran sodium sulfate-induced ulcerative colitis by promoting M2 macrophage polarization. Int. Immunopharmacol.
2019, 72, 264–274. [CrossRef]
130. Wu, Y.; Qiu, W.; Xu, X.; Kang, J.; Wang, J.; Wen, Y.; Tang, X.; Yan, Y.; Qian, H.; Zhang, X.; et al. Exosomes derived from human
umbilical cord mesenchymal stem cells alleviate inflammatory bowel disease in mice through ubiquitination. Am. J. Transl. Res.
2018, 10, 2026–2036.
131. Tian, J.; Zhu, Q.; Zhang, Y.; Bian, Q.; Hong, Y.; Shen, Z.; Xu, H.; Rui, K.; Yin, K.; Wang, S. Olfactory Ecto-Mesenchymal Stem
Cell-Derived Exosomes Ameliorate Experimental Colitis via Modulating Th1/Th17 and Treg Cell Responses. Front. Immunol.
2020, 11, 3249. [CrossRef]
Int. J. Mol. Sci. 2021, 22, 2213 24 of 25
132. Li, Y.-Y.; Xu, Q.-W.; Xu, P.-Y.; Li, W.-M. MSC-derived exosomal miR-34a/c-5p and miR-29b-3p improve intestinal barrier function
by targeting the Snail/Claudins signaling pathway. Life Sci. 2020, 257, 118017. [CrossRef]
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